<?xml version="1.0" encoding="UTF-8"?>
<PAPER>

<BODY>
<DIV><P>
</P>
<P>[0001] <ne id="WO2007038869.HC.class-names.218" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">APTAMERS</ne> COMPRISING ARABINOSE MODIFIED NUCLEOTIDES
Field of the Invention
</P>
<P>[0001] The invention relates generally to <ne id="WO2007038869.HC.class-names.219" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> and more specifically to <ne id="WO2007038869.HC.class-names.220" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> containing at least one <ne id="WO2007038869.HC.class-names.314" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne>.
Background of the Invention
</P>
<P>[0002] <ne id="WO2007038869.HC.class-names.266" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">Oligonucleotide</ne>-based therapeutics have enormous potential for targeted therapy of cancer as well as inflammatory and infectious disease, exhibiting greater specificity and less toxicity than conventional chemotherapeutic drugs. The so-called "antisense" (AON) and "small interfering RNA" (siRNA) are the most prominent members of this class of agents [Stull, R.A. and Szoka, P. C. (1995) Pharmaceutical Research, 12_: 465-483; Uhlmann E. and Peyman, A. (1990) Chemical Reviews, 9_0: 544-584.; Mittal, V. (2004) Nature Rev., 5_: 355-365] . <ne id="WO2007038869.HC.class-names.221" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">Aptamers</ne> and immunostimulatory <ne id="WO2007038869.HC.class-names.207" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">oligonucleotides</ne> are the most recent additions to the large number of nucleic acid molecules being pursued as potential therapeutic agents . AONs and siRNAs are designed to target a specific mRNA, whereas <ne id="WO2007038869.HC.class-names.222" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> and immunostimulatory <ne id="WO2007038869.HC.class-names.208" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">oligonucleotides</ne> generally function by specific protein targets or activating a wide array of immuno effector cells
</P>
<P>[Nimjee, S.M. et al. (2005) Annu. Rev. Med. 5_6: 555-83;
Uhlmann E. and Vollmer J. (2003) Current Opinion in Drug
Discovery &amp; Development jS : 204-217] .
</P>
<P>[0003] Excellent progress towards clinical applications of <ne id="WO2007038869.HC.class-names.223" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> has been made [Hicke, B.J. et al. (1996) J&lt;"&gt;. Clin. Investig. 9[section]: 2688-2692; Pietras, K. et al. (2002) Cancer Res. 62 : 5476-5484; White, R. R. et al. (2003) Proc. Natl. Acad. Sci. U.S.A. 100: 5028-5033)].
<ne id="WO2007038869.HC.class-names.224" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">Aptamers</ne> have gained acceptance with the recent FDA approval of Macugen(R), a sugar-modified RNA analog (<ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.20" epochem-id="EPOCHEM:NEW:COMPOUND:1721" name="2'F-ribose" comment="" chebi-id="WO2007038869:452886" relevant="false">2'F-ribose</ne>, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.21" epochem-id="EPOCHEM:NEW:COMPOUND:1722" name="2' -O-methylribose" comment="" chebi-id="WO2007038869:652412" relevant="false">2' -O-methylribose</ne>, 3'-pegylated <ne id="WO2007038869.HC.class-names.430" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>, M.Wt. 50 kD) indicated for the treatment of neovascular age-related macular degeneration (AMD) [ (a) Eyetech Study Group (2002) Preclinical and phase IA clinical evaluation of an anti-VEGF pegylated <ne id="WO2007038869.HC.class-names.431" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> (EYEOOl) for the treatment of exudative age-related macular degeneration, Retina, 2^: 143-52; (b) Eyetech Study Group (2003) Antivascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results, Ophthalmology, 110 : 979- 86] . <ne id="WO2007038869.HC.class-names.200" epochem-id="EPOCHEM:NEW:CLASS:877" name="Nucleic acid aptamers" comment="" chebi-id="WO2007038869:38029" relevant="false" type="CLASS">Nucleic acid aptamers</ne> have also been shown to control viral gene expression, including HIV, in vitro [(a) Sullenger B.A., Gallardo H. F., Ungers G. E. and Gilboa E.
(1991) Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation, Journal of Virology, ^5_: 6811-6816; (b) Zimmermann K., Weber S., Dobrovnik M., Hauber J. and Bohnlein E. (1992) Expression of chimeric neo-rev response element sequences interferes with rev-dependent HIV-I gag expression, Human Gene Therapy, 3_: 155-161; (c) Lee T. C, Gallardo H. F., Ungers G. E. and Gilboa E. (1992) Overexpression of RRE-derived sequences inhibits HIV-I replication in CEM cells. New Biologist, [pound]: 66-74]. <ne id="WO2007038869.HC.class-names.226" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">Aptamers</ne> may also prove useful for the treatment of other important human maladies, including infectious diseases, cancer, and cardiovascular disease. A common technique by which <ne id="WO2007038869.HC.class-names.202" epochem-id="EPOCHEM:NEW:CLASS:878" name="oligonucleotide aptamers" comment="" chebi-id="WO2007038869:286242" relevant="false" type="CLASS">oligonucleotide aptamers</ne> are obtained relies on the systematic evolution of ligands by exponential enrichment (SELEX) process [Tuerk, C. and Gold, L. (1990) Science, 249, 505-510); Ellington, A.D. and Szostak, J.W. (1990) Nature, 3_4_6: 818-822] . The resulting <ne id="WO2007038869.HC.class-names.209" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">oligonucleotides</ne> are more commonly referred to as "<ne id="WO2007038869.HC.class-names.228" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne>" , derived from the Latin word "aptus" , meaning "to fit" . These single- or double-stranded molecules are typically capable of binding proteins and, as such, serve as "sinks" by blocking the protein from further function [Baltimore D. (1988) Nature 335: 395-396] .
</P>
<P>[0004] The utility of <ne id="WO2007038869.HC.class-names.201" epochem-id="EPOCHEM:NEW:CLASS:877" name="Nucleic acid aptamers" comment="" chebi-id="WO2007038869:38029" relevant="false" type="CLASS">nucleic acid aptamers</ne> in vivo and their possible application in pharmacotherapy, as with other <ne id="WO2007038869.HC.class-names.268" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne>-based therapies, face some key hurdles e.g., delivery, cellular uptake and biostability. There is a need to develop chemical modifications to produce clinically useful molecules. Initial work with <ne id="WO2007038869.HC.class-names.529" epochem-id="EPOCHEM:NEW:CLASS:402" name="oligodeoxynucleotides" comment="" chebi-id="WO2007038869:238446" relevant="false" type="CLASS">oligodeoxynucleotides</ne> (DNA) was undertaken with unmodified, natural molecules.
It soon became clear however, that native DNA was subject to relatively rapid degradation, primarily through the action of 3' exonucleases, but as a result of endonuclease attack as well . <ne id="WO2007038869.HC.class-names.390" epochem-id="EPOCHEM:NEW:CLASS:895" name="Oligoribonucleotides" comment="" chebi-id="WO2007038869:484005" relevant="false" type="CLASS">Oligoribonucleotides</ne> (RNA) are subject to the same considerations and are, in fact, generally more susceptible to nuclease degradation. The same issues apply to <ne id="WO2007038869.HC.class-names.230" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> where nuclease stability is highly desirable. Given that the protein binding activity of <ne id="WO2007038869.HC.class-names.231" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> is strongly dependent on the folding of the <ne id="WO2007038869.HC.class-names.269" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> structure (3D structure) , it is highly desirable that such structure is of high thermal stability.
</P>
<P>[0005] Until now, several methods have been devised to improve the stability of <ne id="WO2007038869.HC.class-names.232" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne>, most of which make use of SELEX.
Nolte et al. have reported a mirror-design RNA aptatner (or "Spiegelmers") , which consists of selecting a normal <ne id="WO2007038869.HC.class-names.203" epochem-id="EPOCHEM:NEW:CLASS:879" name="RNA aptamer" comment="" chebi-id="WO2007038869:276530" relevant="false" type="CLASS">RNA aptamer</ne> (D-RNA) against the enantiomer of a target protein, the mirror image of the target protein (<ne id="WO2007038869.HC.class-names.206" epochem-id="EPOCHEM:NEW:CLASS:880" name="D-aminoacids" comment="D-amino acids" chebi-id="WO2007038869:539068" relevant="false" type="CLASS">D-amino acids</ne>) , by using standard SELEX. When the resulting <ne id="WO2007038869.HC.class-names.204" epochem-id="EPOCHEM:NEW:CLASS:879" name="RNA aptamer" comment="" chebi-id="WO2007038869:276530" relevant="false" type="CLASS">RNA aptamer</ne> (D-RNA) is converted to its enantiomeric form, L-RNA, with the same base composition, the L-RNA exhibits high binding affinity to the native protein molecule (<ne id="WO2007038869.HC.class-names.388" epochem-id="EPOCHEM:NEW:CLASS:893" name="L-aminoacids" comment="L-amino acids" chebi-id="WO2007038869:927057" relevant="false" type="CLASS">L-amino acids</ne>) and high resistance against cleavage by nucleases. This strategy is limited to cases where an enantiomer of the target molecule is available [Nolte,A. et al. (1996) Nat. Biotechnol . , 14: 1116- 1119] . Another method for the stabilizing RNA <ne id="WO2007038869.HC.class-names.233" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> consists of a chemical modification after the RNA molecules have been selected by SELEX.
Normally such modifications are introduced by incorporation of <ne id="WO2007038869.HC.class-names.145" epochem-id="EPOCHEM:NEW:CLASS:615" name="2' -O-methylribonucleotides" comment="" chebi-id="WO2007038869:355215" relevant="false" type="CLASS">2' -O-methylribonucleotides</ne> into the native RNA structure. However, this strategy causes structural changes of the RNA molecules and often results in loss of <ne id="WO2007038869.HC.class-names.205" epochem-id="EPOCHEM:NEW:CLASS:879" name="RNA aptamer" comment="" chebi-id="WO2007038869:276530" relevant="false" type="CLASS">RNA aptamer</ne> activity [Lebruska,L.L. and Maher,L.J. (1999) Biochemistry, 3J3: 3168-3174] . A variation of the SELEX method generates nuclease resistant RNA molecules by employing modified <ne id="WO2007038869.HC.class-names.152" epochem-id="EPOCHEM:NEW:CLASS:619" name="nucleoside triphosphates" comment="" chebi-id="CHEBI:17326" relevant="false" type="CLASS">nucleoside triphosphates</ne> instead of the natural substrates (dNTPs or rNTPs) [U.S. Pat. No. 5,660,985, both entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides", and U.S. Pat. No. 6,387,620, entitled "Transcription-free SELEX"] . However, some of these chemistries are incompatible with SELEX as the monomeric <ne id="WO2007038869.HC.class-names.146" epochem-id="EPOCHEM:NEW:CLASS:616" name="5'- triphosphates" comment="" chebi-id="WO2007038869:798538" relevant="false" type="CLASS">5'- triphosphates</ne> units are not substrates of DNA/RNA polymerases. Thus far, <ne id="WO2007038869.HC.class-names.150" epochem-id="EPOCHEM:NEW:CLASS:617" name="2' -modified-2' -deoxynucleoside 5' -triphosphates" comment="" chebi-id="WO2007038869:988765" relevant="false" type="CLASS">2' -modified-2' -deoxynucleoside 5' -triphosphates</ne> [Pagratis,N.C. , et al .
(1997) Wat. Biotechnol., 15_&lt;:&gt; 68-73], <ne id="WO2007038869.HC.class-names.386" epochem-id="EPOCHEM:NEW:CLASS:891" name="nucleoside 5' - (alpha-P-borano) triphosphates" comment="" chebi-id="WO2007038869:753151" relevant="false" type="CLASS">nucleoside 5' - (alpha-P-borano) triphosphates</ne> [Lato, S.M. (2002) Nucleic Acids Res., 30: 1401-1407], <ne id="WO2007038869.HC.class-names.387" epochem-id="EPOCHEM:NEW:CLASS:892" name="nucleoside 5'-(alpha- thio) triphosphates" comment="" chebi-id="WO2007038869:624096" relevant="false" type="CLASS">nucleoside 5'-(alpha- thio) triphosphates</ne> [Jhaveri,S. et al . (1998) Bioorg. Med. Chem. Lett., J3: 2285-2290], and more recently, <ne id="WO2007038869.HC.class-names.151" epochem-id="EPOCHEM:NEW:CLASS:618" name="4'- thioribonucleoside 5' -triphosphates" comment="" chebi-id="WO2007038869:176971" relevant="false" type="CLASS">4'- thioribonucleoside 5' -triphosphates</ne> [Kato, Y. et al. (2005) Nucleic Acids Res. 33 : 2942-2951] are the most used triphosphates for SELEX. Among these, 2' -modified rNTPs, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.24" epochem-id="EPOCHEM:NEW:COMPOUND:1723" name="2'- fluoro-2' -deoxy-ribopyrimidine" comment="" chebi-id="WO2007038869:518470" relevant="false">2'- fluoro-2' -deoxy-ribopyrimidine</ne> (2'F-RNA) and <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.25" epochem-id="EPOCHEM:NEW:COMPOUND:1724" name="2'-amino-2'- deoxy-ribopyrimidine" comment="" chebi-id="WO2007038869:119223" relevant="false">2'-amino-2'- deoxy-ribopyrimidine</ne> (<ne id="WO2007038869.HC.class-names.389" epochem-id="EPOCHEM:NEW:CLASS:894" name="2'-NH2-RNA" comment="" chebi-id="WO2007038869:166344" relevant="false" type="CLASS">2'-NH2-RNA</ne>) <ne id="WO2007038869.HC.class-names.153" epochem-id="EPOCHEM:NEW:CLASS:619" name="nucleoside triphosphates" comment="" chebi-id="CHEBI:17326" relevant="false" type="CLASS">nucleoside triphosphates</ne> are frequently used. A number of nuclease-resistant RNAs, including the vascular endothelial growth factor-binding <ne id="WO2007038869.HC.class-names.435" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>, Macugen, were isolated using primarily 2'F-rU/rC and 2'-<ne type="LIGAND" id="WO2007038869.HC.ligand-names.67" epochem-id="EPOCHEM:NEW:LIGAND:608" name="NH2" comment="" chebi-id="CHEBI:46882" relevant="false">NH2</ne>-rU/rC <ne id="WO2007038869.HC.class-names.149" epochem-id="EPOCHEM:NEW:CLASS:616" name="5'- triphosphates" comment="" chebi-id="WO2007038869:798538" relevant="false" type="CLASS">5' -triphosphates</ne> [Ruckman, J. (1998) J. Biol. Chem. 273: 20556-20567] .
</P>
<P>[0006] A DNA <ne id="WO2007038869.HC.class-names.436" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> targeted toward thrombin, a key protease involved in the blood clotting cascade, has been identified and related studies have been performed. This <ne id="WO2007038869.HC.class-names.437" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>, first identified via SELEX, consists of a 15-nt sequence containing six thymidine (dT) and nine deoxyguanosine
(dG) nucleotides, namely <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.137" epochem-id="EPOCHEM:NEW:COMPOUND:2106" name="5' -dGGTTGGTGTGGTTGG-3'" comment="" chebi-id="WO2007038869:917403" relevant="false">5' -dGGTTGGTGTGGTTGG-3'</ne> . Under certain conditions, this <ne id="WO2007038869.HC.class-names.270" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> is known to fold into a quadruplex structure, which contains two G-quartets and three lateral loops, usually referred to as a "chair structure"
(Figure 1) [Bock, L. C. et al. (1992) Nature 355: 564] . Each quartet adopts a square planar configuration, each dG residue interacting with the adjacent one via two hydrogen bonds and behaving as both H-bond acceptor and donor. Potassium ions stabilize the entire structure by coordination to the <ne id="WO2007038869.HC.class-names.391" epochem-id="EPOCHEM:NEW:CLASS:896" name="guanine" comment="" chebi-id="CHEBI:16235" relevant="false" type="CLASS">guanine</ne> bases. A similar folding was reported on the crystal structure of the <ne id="WO2007038869.HC.class-names.438" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>-thrombin complex [Padmanabhan, K. et al. (1993) J&lt;"&gt;. Biol. Chem. 268: 17651] . There are several other examples of G-quadruplex structures reported in the literature, some of which are being tested as therapeutic agents themselves, specifically as antivirals and anticancer agents [see Sacca, B. et al. (2005) Nucleic Acids Res. 33 : 1182-119, and references therein] .
</P>
<P>[0007] Several studies aimed at modifying this <ne id="WO2007038869.HC.class-names.439" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> have been reported, but very few, if any, have led to an improvement over the original molecule.
For example, Heckel and Mayer reported that the introduction of thymines modified with a nitrophenylpropyl moiety (T-NPP) at certain positions generally abolished interaction of the <ne id="WO2007038869.HC.class-names.440" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> with thrombin [Heckel, A. and Mayer, G. (2005) J. Am. Chem. Soc. 127: 822- 823] . Di Giusto and King reported the synthesis of circular <ne id="WO2007038869.HC.class-names.234" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> targeted against thrombin with improved nuclease resistance and anticoagulant activity compared to those of the canonical thrombin DNA <ne id="WO2007038869.HC.class-names.441" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> [Di Giusto, D.A. and King, G. C. (2004; J. Biol. Chem. 279: 46483-46489] . However, circularization of the <ne id="WO2007038869.HC.class-names.235" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> produces a mixture of constructs and requires a ligase enzyme, making the method very difficult to scale-up. Other attempts to circularize the thrombin-binding DNA <ne id="WO2007038869.HC.class-names.442" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> via chemical methods abolished the anti-thrombin activity [Buijsman, R. C. et al. (1997) Bioorg.Med. Chem.
Letters 2&lt;:&gt; 2027-2032]. Recently, Seela and coworkers reported the insertion of a hairpin-forming sequence GCGAAG into the position of the central loop of the thrombin- binding <ne id="WO2007038869.HC.class-names.443" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>. This construct was able to form both a G- quartet and a joined minihairpin structure. According to the Tn, data, the minihairpin induces a structural change in the <ne id="WO2007038869.HC.class-names.444" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> section. Binding to thrombin was not investigated [Rosemeyer, H. et al . (2004) Helvetica Chimica Acta 87: 536-552] . Sacca et al . studied the effect of backbone charge and atom size, base substitutions as well as the effect of modification at the sugar 2 '-position as analyzed by spectroscopy. All sugar (<ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.27" epochem-id="EPOCHEM:NEW:COMPOUND:1725" name="ribose" comment="" chebi-id="CHEBI:33942" relevant="false">ribose</ne>, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.22" epochem-id="EPOCHEM:NEW:COMPOUND:1722" name="2' -O-methylribose" comment="" chebi-id="WO2007038869:652412" relevant="false">2' -O-methylribose</ne>) and phosphate (<ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.45" epochem-id="EPOCHEM:NEW:COMPOUND:1726" name="methylphosphonate" comment="" chebi-id="CHEBI:45129" relevant="false">methylphosphonate</ne>, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.48" epochem-id="EPOCHEM:NEW:COMPOUND:1727" name="phosphorothioate" comment="" chebi-id="WO2007038869:297068" relevant="false">phosphorothioate</ne>) led to a reduction in the thermal stability of the <ne id="WO2007038869.HC.class-names.445" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> [Sacca, B. et al. (2005) Nucleic Acids Res. 3_3: 1182-1192] . In fact, the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.23" epochem-id="EPOCHEM:NEW:COMPOUND:1722" name="2' -O-methylribose" comment="" chebi-id="WO2007038869:652412" relevant="false">2' -O-methylribose</ne> modification led not only to a destabilization of the structure, but also to a complete changing of the G-quartet conformation. As such, the structure of the thrombin <ne id="WO2007038869.HC.class-names.446" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> is particularly sensitive to chemical modifications. Furthermore, previous studies have shown that replacing the native DNA bases by modified bases generally disrupt the <ne id="WO2007038869.HC.class-names.447" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> structure.
</P>
<P>[0008] The <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.49" epochem-id="EPOCHEM:NEW:COMPOUND:1727" name="phosphorothioate" comment="" chebi-id="WO2007038869:297068" relevant="false">phosphorothioate</ne> octanucleotide dTTGGGGTT [PS- dT2G4T2] is a compound that binds to the viral envelope protein gpl20 of the human immunodeficiency virus (HIV) , preventing fusion of HIV to the cellular CD4 receptor [Wyatt J.R. et al.
(1994) Proc.Nat.Acad.Sci. USA 9_0: 1356-1360] . PS-dT2G4T2 forms a parallel-stranded tetramer stabilized by G-quartets (G- tetrads) . Wyatt et al. [Proc.Nat.Acad.Sci. USA 9_0: 1356-1360] also showed that its <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.62" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> structure and certain <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.50" epochem-id="EPOCHEM:NEW:COMPOUND:1727" name="phosphorothioate" comment="" chebi-id="WO2007038869:297068" relevant="false">phosphorothioate</ne> linkages were necessary for inhibition of viral infection [Stoddart, CA. et al . (1998) Antimicrob Agents Chemother. [pound]2: 2113-2115] .
</P>
<P>[0009] The <ne id="WO2007038869.HC.class-names.174" epochem-id="EPOCHEM:NEW:CLASS:621" name="oligomer" comment="" chebi-id="WO2007038869:267706" relevant="false" type="CLASS">oligomer</ne> dGGGGTTTTGGGG is derived from the <ne id="WO2007038869.HC.class-names.177" epochem-id="EPOCHEM:NEW:CLASS:622" name="telomere" comment="" chebi-id="WO2007038869:271235" relevant="false" type="CLASS">telomere</ne> d (T4G4) repeat of Oxytricha [Smith, F.W. and Feigon, J. (1992) Nature, 356: 164-168) . NMR studies showed that this compound, like the antithrombin <ne id="WO2007038869.HC.class-names.448" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>, forms a G-quartet structure [Smith, F.W. and Feigon, J. (1992) Nature, 356: 164- 168; Smith F.W. and Feigon J.. (1993) Biochemistry 32: 8682] . As G-tetrads are found in human telomeres, they are of particular interest for anticancer drug discovery efforts. These <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.63" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> structures may be used to inhibit <ne id="WO2007038869.HC.class-names.178" epochem-id="EPOCHEM:NEW:CLASS:622" name="telomere" comment="" chebi-id="WO2007038869:271235" relevant="false" type="CLASS">telomere</ne> extension (by inhibiting telomerase) , a process that occurs selectively in cancer cells [Kerwin, M. (2000) Current Pharmaceutical Design [pound]: 441-471] .
</P>
<P>[0010] The anti-thrombin <ne id="WO2007038869.HC.class-names.175" epochem-id="EPOCHEM:NEW:CLASS:621" name="oligomer" comment="" chebi-id="WO2007038869:267706" relevant="false" type="CLASS">oligomer</ne> dGGTTGGTGTGGTTGG displays a characteristic circular dichroism (CD) spectrum, referred to as a "Type II" CD spectrum. A type II CD profile is indicative of a unimolecular G-quartet in which two of the <ne id="WO2007038869.HC.class-names.392" epochem-id="EPOCHEM:NEW:CLASS:896" name="guanine" comment="" chebi-id="CHEBI:16235" relevant="false" type="CLASS">guanine</ne> residues are in the anti conformation, and the two others in the syn conformation [Macaya, R. F. et al. (1993) Proc. Natl. Acad. [Xi]ci. U. S. A., j&gt;[pound]: 3745-3749]. The term G
(anti) refers to a guanosine nucleoside structure in which the <ne id="WO2007038869.HC.class-names.393" epochem-id="EPOCHEM:NEW:CLASS:896" name="guanine" comment="" chebi-id="CHEBI:16235" relevant="false" type="CLASS">guanine</ne> base is oriented away from the sugar ring to which is attached, whereas in the G (syn) conformation the <ne id="WO2007038869.HC.class-names.394" epochem-id="EPOCHEM:NEW:CLASS:896" name="guanine" comment="" chebi-id="CHEBI:16235" relevant="false" type="CLASS">guanine</ne> base is placed directly above the sugar ring structure. The anti and syn conformational change comes about the rotation of the Cl'-N9 glycosidic bond [W. Saenger, in "Principles of Nucleic Acids Structure", CR. Cantor (editor); Springer-Verlag, 1983] . The "Type II" CD spectrum display a positive band at - 295 nm and a negative band at ~ 260 nm. On the other hand, a
"Type I" CD spectrum displays a positive CD band at -265 nm and a negative band at ~ 240 nm that correlates with a intermolecular <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.64" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> with only G (anti) residues
</P>
<P>[Williamson, J. R. (1994) G-Quartet Structures in Telomeric DNA. A[pi][pi]u. Rev. Biophys. Biomol. Struct. 23^ 703-730]. Thus these two types of CD spectra strongly correlate to the conformation of the G-quartet core.
</P>
<P>[0011] The telomeric dGGGGTTTTGGGG sequence, like the anti- thrombin sequence described above, exhibits a Type II CD spectrum, consistent with a <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.65" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> with guanines in both syn and anti conformations (Lu, M. et al. (1993) Biochemistry, 32: 598-601; Smith, F.W. and Feigon, J. (1992) Nature, 356: 164- 168) . By contrast, the sequence dTTGGGGTT (either with <ne id="WO2007038869.HC.class-names.179" epochem-id="EPOCHEM:NEW:CLASS:623" name="phosphodiester" comment="" chebi-id="WO2007038869:218685" relevant="false" type="CLASS">phosphodiester</ne> linkage (PO) or <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.54" epochem-id="EPOCHEM:NEW:COMPOUND:1728" name="phosphothioate" comment="" chebi-id="WO2007038869:886878" relevant="false">phosphothioate</ne> linkage (PS) ) shows a Type I CD spectrum, resulting from a G-quadruplex structure in which all <ne id="WO2007038869.HC.class-names.395" epochem-id="EPOCHEM:NEW:CLASS:896" name="guanine" comment="" chebi-id="CHEBI:16235" relevant="false" type="CLASS">guanine</ne> bases adopt the anti conformation (Wyatt, J. R. et al . (1994) Proc. Natl. Acad. Sci. U.S.A. , [pound]1: 1356-1360) .
</P>
<P>[0012] There is a need in the art to improve the nuclease stability of <ne id="WO2007038869.HC.class-names.236" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> generally including, in particular, those that are capable of forming a <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.66" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> such as those described above. Furthermore, it is preferable that such modification does not significantly decrease the subtle binding interaction of the selected native <ne id="WO2007038869.HC.class-names.449" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>.
Summary of the Invention
</P>
<P>[0013] According to one broad aspect of the invention, nucleic acid ligands (or <ne id="WO2007038869.HC.class-names.237" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne>) capable of forming a <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.67" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G- tetrad</ne> and comprising at least one <ne id="WO2007038869.HC.class-names.315" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne> are provided. Preferably, the <ne id="WO2007038869.HC.class-names.316" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne> is <ne id="WO2007038869.HC.class-names.326" epochem-id="EPOCHEM:NEW:CLASS:889" name="2'-deoxy-2'- fluoroarabinonucleotide" comment="" chebi-id="WO2007038869:932062" relevant="false" type="CLASS">2' -deoxy-2' -fluoroarabinonucleotide</ne> (<ne id="WO2007038869.HC.class-names.333" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>). The <ne id="WO2007038869.HC.class-names.317" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne> is preferably in the loop of the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.68" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-Tetrad</ne> or alternatively a guanosine residue of the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.69" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne>.
</P>
<P>[0014] In a preferred embodiment of the invention the <ne id="WO2007038869.HC.class-names.450" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> is an antithrombin <ne id="WO2007038869.HC.class-names.451" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>, preferably having the sequence: dGGTTGGTGTGGTTGG (15-nt) .
</P>
<P>[0015] In another preferred embodiment the <ne id="WO2007038869.HC.class-names.452" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> is an anti-HIV <ne id="WO2007038869.HC.class-names.453" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>, preferably having the sequence: dT2G4T2 (8- nt) .
</P>
<P>[0016] In another preferred embodiment of the invention the <ne id="WO2007038869.HC.class-names.454" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> comprises a dG4T4 repeat, preferably dG4T4G4 (12-nt) , dG4T4G4T4G4 (20-nt), and dG4T4G4T4G4T4G4 (28-nt) .
</P>
<P>[0017] In specific embodiments of the invention, the <ne id="WO2007038869.HC.class-names.455" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> has a sequence according any one of SEQ ID NOS. 1-3, 4-14, 19-24 and 26-28. [0018] In specific embodiments, the <ne id="WO2007038869.HC.class-names.456" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> may have any number of arabinonucleotides at any location in the <ne id="WO2007038869.HC.class-names.457" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>, for example:
</P>
<P>5 ' -ADADADADADADADA-3 ' 5 ' -AADADDADDDAADAD-3 '
</P>
<P>5 ' -AAAADAAADADDDAD-3 '
etc .
wherein A is an arabinonucleotide and D is a <ne id="WO2007038869.HC.class-names.526" epochem-id="EPOCHEM:NEW:CLASS:898" name="2'- deoxyribonucleotide" comment="" chebi-id="WO2007038869:739386" relevant="false" type="CLASS">2'- deoxyribonucleotide</ne> .
</P>
<P>[0019] In other embodiments of the invention, the <ne id="WO2007038869.HC.class-names.458" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> is fully substituted with arabinonucleotides. For example:
</P>
<P>5' -AAAAAAAAAAAAAAA-3'
</P>
<P>[0020] In a preferred embodiment of the present invention, chimeras constructed from <ne id="WO2007038869.HC.class-names.527" epochem-id="EPOCHEM:NEW:CLASS:898" name="2'- deoxyribonucleotide" comment="" chebi-id="WO2007038869:739386" relevant="false" type="CLASS">2' -deoxyribonucleotide</ne> (DNA) and <ne id="WO2007038869.HC.class-names.327" epochem-id="EPOCHEM:NEW:CLASS:889" name="2'-deoxy-2'- fluoroarabinonucleotide" comment="" chebi-id="WO2007038869:932062" relevant="false" type="CLASS">2'- deoxy-2' -fluoroarabinonucleotide</ne> (<ne id="WO2007038869.HC.class-names.334" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>) capable of binding thrombin selectively are provided.
</P>
<P>[0021] In other embodiments of the invention, an <ne id="WO2007038869.HC.class-names.459" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of sequence 5'-GGTTGGTGTGGTTGG-S', dT2G4T2 and d [G4T4G4Jn is provided having a sugar-phosphate backbone composition selected from any combination of arabinose and <ne id="WO2007038869.HC.class-names.530" epochem-id="EPOCHEM:NEW:CLASS:1113" name="deoxyribose nucleotides" comment="" chebi-id="WO2007038869:992023" relevant="false" type="CLASS">deoxyribose nucleotides</ne>. Preferably, the <ne id="WO2007038869.HC.class-names.531" epochem-id="EPOCHEM:NEW:CLASS:1114" name="arabinose nucleotides" comment="" chebi-id="WO2007038869:973858" relevant="false" type="CLASS">arabinose nucleotides</ne> are <ne id="WO2007038869.HC.class-names.328" epochem-id="EPOCHEM:NEW:CLASS:889" name="2'-deoxy-2'- fluoroarabinonucleotide" comment="" chebi-id="WO2007038869:932062" relevant="false" type="CLASS">2'- deoxy-2' -fluoroarabinonucleotide</ne> (<ne id="WO2007038869.HC.class-names.335" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>) .
</P>
<P>[0022] In other embodiments of the invention, the arabinonucleotide comprises a 2' substituent selected from the group consisting of <ne type="LIGAND" id="WO2007038869.HC.ligand-names.63" epochem-id="EPOCHEM:NEW:LIGAND:352" name="fluorine" comment="" chebi-id="CHEBI:24061" relevant="false">fluorine</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.25" epochem-id="EPOCHEM:NEW:LIGAND:1" name="hydroxyl" comment="" chebi-id="CHEBI:29191" relevant="false">hydroxyl</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.57" epochem-id="EPOCHEM:NEW:LIGAND:590" name="amino" comment="" chebi-id="CHEBI:46882" relevant="false">amino</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.31" epochem-id="EPOCHEM:NEW:LIGAND:515" name="azido" comment="" chebi-id="CHEBI:36825" relevant="false">azido</ne>, <ne id="WO2007038869.HC.class-names.532" epochem-id="EPOCHEM:NEW:CLASS:1115" name="alkyl" comment="" chebi-id="CHEBI:22323" relevant="false" type="CLASS">alkyl</ne>, <ne id="WO2007038869.HC.class-names.539" epochem-id="EPOCHEM:NEW:CLASS:1116" name="alkoxy" comment="" chebi-id="CHEBI:22338" relevant="false" type="CLASS">alkoxy</ne>, and <ne id="WO2007038869.HC.class-names.310" epochem-id="EPOCHEM:NEW:CLASS:886" name="alkoxyalkyl groups" comment="" chebi-id="WO2007038869:614727" relevant="false" type="CLASS">alkoxyalkyl groups</ne>.
In a further embodiment of the invention, the <ne id="WO2007038869.HC.class-names.307" epochem-id="EPOCHEM:NEW:CLASS:864" name="alkyl group" comment="" chebi-id="CHEBI:22323" relevant="false" type="CLASS">alkyl group</ne> is selected from the group consisting of <ne type="LIGAND" id="WO2007038869.HC.ligand-names.55" epochem-id="EPOCHEM:NEW:LIGAND:457" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.53" epochem-id="EPOCHEM:NEW:LIGAND:458" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.51" epochem-id="EPOCHEM:NEW:LIGAND:520" name="propyl" comment="" chebi-id="CHEBI:26308" relevant="false">propyl</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.49" epochem-id="EPOCHEM:NEW:LIGAND:519" name="butyl" comment="" chebi-id="CHEBI:41264" relevant="false">butyl</ne>, and functionalized <ne id="WO2007038869.HC.class-names.305" epochem-id="EPOCHEM:NEW:CLASS:885" name="alkyl groups" comment="" chebi-id="CHEBI:22323" relevant="false" type="CLASS">alkyl groups</ne> such as <ne type="LIGAND" id="WO2007038869.HC.ligand-names.40" epochem-id="EPOCHEM:NEW:LIGAND:516" name="ethylamino" comment="" chebi-id="WO2007038869:857721" relevant="false">ethylamino</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.43" epochem-id="EPOCHEM:NEW:LIGAND:517" name="propylamino" comment="" chebi-id="WO2007038869:230924" relevant="false">propylamino</ne> and <ne type="LIGAND" id="WO2007038869.HC.ligand-names.46" epochem-id="EPOCHEM:NEW:LIGAND:518" name="butylamino" comment="" chebi-id="WO2007038869:893212" relevant="false">butylamino</ne> groups. In embodiments, the <ne id="WO2007038869.HC.class-names.302" epochem-id="EPOCHEM:NEW:CLASS:884" name="alkoxy group" comment="" chebi-id="WO2007038869:813809" relevant="false" type="CLASS">alkoxy group</ne> is selected from the group consisting of <ne type="LIGAND" id="WO2007038869.HC.ligand-names.8" epochem-id="EPOCHEM:NEW:LIGAND:94" name="methoxy" comment="" chebi-id="WO2007038869:845772" relevant="false">methoxy</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.10" epochem-id="EPOCHEM:NEW:LIGAND:4" name="ethoxy" comment="" chebi-id="CHEBI:42241" relevant="false">ethoxy</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.12" epochem-id="EPOCHEM:NEW:LIGAND:481" name="proproxy" comment="" chebi-id="WO2007038869:290197" relevant="false">proproxy</ne> and functionalized <ne id="WO2007038869.HC.class-names.300" epochem-id="EPOCHEM:NEW:CLASS:883" name="alkoxy groups" comment="" chebi-id="CHEBI:22338" relevant="false" type="CLASS">alkoxy groups</ne> such as <ne type="LIGAND" id="WO2007038869.HC.ligand-names.14" epochem-id="EPOCHEM:NEW:LIGAND:482" name="-O(CH2)q-R" comment="" chebi-id="WO2007038869:713628" relevant="false">-O(CH2)q-R</ne>, where q=2-4 and -R is a -<ne type="LIGAND" id="WO2007038869.HC.ligand-names.68" epochem-id="EPOCHEM:NEW:LIGAND:608" name="NH2" comment="" chebi-id="CHEBI:46882" relevant="false">NH2</ne>, -<ne type="LIGAND" id="WO2007038869.HC.ligand-names.21" epochem-id="EPOCHEM:NEW:LIGAND:421" name="OCH3" comment="" chebi-id="WO2007038869:95589" relevant="false">OCH3</ne>, or -<ne type="LIGAND" id="WO2007038869.HC.ligand-names.1" epochem-id="EPOCHEM:NEW:LIGAND:478" name="OCH2CH3" comment="" chebi-id="WO2007038869:936730" relevant="false">OCH2CH3</ne> group. In embodiments, the <ne id="WO2007038869.HC.class-names.312" epochem-id="EPOCHEM:NEW:CLASS:887" name="alkoxyalkyl group" comment="" chebi-id="WO2007038869:828081" relevant="false" type="CLASS">alkoxyalkyl group</ne> is selected from the group consisting of <ne type="LIGAND" id="WO2007038869.HC.ligand-names.4" epochem-id="EPOCHEM:NEW:LIGAND:479" name="methoxyethyl" comment="" chebi-id="WO2007038869:897528" relevant="false">methoxyethyl</ne> , and <ne type="LIGAND" id="WO2007038869.HC.ligand-names.6" epochem-id="EPOCHEM:NEW:LIGAND:480" name="ethoxyethyl" comment="" chebi-id="WO2007038869:920070" relevant="false">ethoxyethyl</ne> . In embodiments, the 2' substituent is <ne type="LIGAND" id="WO2007038869.HC.ligand-names.64" epochem-id="EPOCHEM:NEW:LIGAND:352" name="fluorine" comment="" chebi-id="CHEBI:24061" relevant="false">fluorine</ne> and the arabinonucleotide is a <ne id="WO2007038869.HC.class-names.549" epochem-id="EPOCHEM:NEW:CLASS:1117" name="2'- fluoroarabinonucleotide" comment="" chebi-id="WO2007038869:855918" relevant="false" type="CLASS">2'- fluoroarabinonucleotide</ne> (<ne id="WO2007038869.HC.class-names.336" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>) . Preferably, the <ne id="WO2007038869.HC.class-names.337" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> nucleotide is araF-G and araF-T.
</P>
<P>[0023] In other embodiments of the invention, the <ne id="WO2007038869.HC.class-names.460" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> comprises one or more internucleotide linkages selected from the group consisting of:
a) <ne id="WO2007038869.HC.class-names.180" epochem-id="EPOCHEM:NEW:CLASS:623" name="phosphodiester" comment="" chebi-id="WO2007038869:218685" relevant="false" type="CLASS">phosphodiester</ne>,- b) <ne id="WO2007038869.HC.class-names.196" epochem-id="EPOCHEM:NEW:CLASS:629" name="phosphotriester" comment="" chebi-id="WO2007038869:606591" relevant="false" type="CLASS">phosphotriester</ne>;
c) <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.51" epochem-id="EPOCHEM:NEW:COMPOUND:1727" name="phosphorothioate" comment="" chebi-id="WO2007038869:297068" relevant="false">phosphorothioate</ne>;
d) <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.46" epochem-id="EPOCHEM:NEW:COMPOUND:1726" name="methylphosphonate" comment="" chebi-id="CHEBI:45129" relevant="false">methylphosphonate</ne>,-
e) <ne id="WO2007038869.HC.class-names.198" epochem-id="EPOCHEM:NEW:CLASS:630" name="boranophosphate" comment="" chebi-id="WO2007038869:315530" relevant="false" type="CLASS">boranophosphate</ne> and
f) any combination of (a) to (e) .
</P>
<P>[0024] According to another broad aspect of the invention, a method for increasing at least one of nuclease stability or selective binding of an <ne id="WO2007038869.HC.class-names.461" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> is provided. The method comprises replacing at least one nucleotide of the <ne id="WO2007038869.HC.class-names.462" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>, preferably in a loop of an <ne id="WO2007038869.HC.class-names.463" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> that forms a <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.70" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne>, with an <ne id="WO2007038869.HC.class-names.318" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne>, preferably <ne id="WO2007038869.HC.class-names.329" epochem-id="EPOCHEM:NEW:CLASS:889" name="2'-deoxy-2'- fluoroarabinonucleotide" comment="" chebi-id="WO2007038869:932062" relevant="false" type="CLASS">2'-deoxy-2'- fluoroarabinonucleotide</ne> (<ne id="WO2007038869.HC.class-names.338" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>) .
</P>
<P>[0025] According to another broad aspect of the invention a pharmaceutical composition is provided, comprising the <ne id="WO2007038869.HC.class-names.464" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of the present invention along with a pharmaceutically acceptable carrier.
</P>
<P>[0026] According to another broad aspect of the invention, a use of an <ne id="WO2007038869.HC.class-names.465" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of the present invention is provided for the preparation of a medicament for inhibiting thrombin. [0027] According to another broad aspect of the invention, a use of an <ne id="WO2007038869.HC.class-names.466" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of the present invention is provided for the preparation of a medicament for treating or preventing HIV infection.
</P>
<P>[0028] According to another broad aspect of the invention, a use of an <ne id="WO2007038869.HC.class-names.467" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of the present invention is provided for the preparation of a medicament for treating or preventing cancer.
</P>
<P>[0029] According to another broad aspect of the invention, a method of inhibiting thrombin or preventing or treating HIV or cancer in a patient in need thereof is provided. The method comprises administering to the patient a therapeutically effective amount of the pharmaceutical composition of the invention.
</P>
<P>[0030] According to another broad aspect of the invention a commercial package is provided. The commercial package comprises the pharmaceutical composition of the present invention together with instructions for its use.
Brief Descriptions of the Drawings
</P>
<P>[0031] The invention will now be described in greater detail having regard to the appended drawings in which:
</P>
<P>[0032] Figure 1 illustrates the <ne id="WO2007038869.HC.class-names.396" epochem-id="EPOCHEM:NEW:CLASS:896" name="guanine" comment="" chebi-id="CHEBI:16235" relevant="false" type="CLASS">guanine</ne> quadruplex (G- quartet) (Left) and diagram of the intramolecular G-quartet of the thrombin binding DNA <ne id="WO2007038869.HC.class-names.468" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> (Right) . The structure of <ne id="WO2007038869.HC.class-names.339" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> units (thymine and <ne id="WO2007038869.HC.class-names.397" epochem-id="EPOCHEM:NEW:CLASS:896" name="guanine" comment="" chebi-id="CHEBI:16235" relevant="false" type="CLASS">guanine</ne> base) is also shown (bottom left) .
</P>
<P>[0033] Figures 2a and 2b illustrates thermal melting profiles measured at 295 nm in <ne type="ONT" id="WO2007038869.HC.class-names.400" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> a) 10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.108" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>, pH 6.8; b) 10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.109" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>, pH 6.8, 25mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.23" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, at a final strand concentration of 8 [mu]M. The Tm (melting temperature) data is provided in Table 1. [0034] Figure 3 illustrates Tm versus concentration dependence study carried out in a <ne type="ONT" id="WO2007038869.HC.class-names.401" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> consisting of 10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.110" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>, pH 6.8, 25mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.24" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>.
</P>
<P>[0035] Figure 4 illustrates heating and cooling Tm transitions of G-tetrads formed by arabinose modified <ne id="WO2007038869.HC.class-names.210" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">oligonucleotides</ne> and control DNA <ne id="WO2007038869.HC.class-names.271" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> in a <ne type="ONT" id="WO2007038869.HC.class-names.402" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> of 10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.111" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>, 25mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.25" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, pH 6.8, at a final strand concentration of 8 [mu]M.
</P>
<P>[0036] Figure 5 illustrates CD spectra of <ne id="WO2007038869.HC.class-names.211" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">oligonucleotides</ne> in a <ne type="ONT" id="WO2007038869.HC.class-names.403" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> consisting of 10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.112" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>, pH 6.8 without/with 25mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.26" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne> at 15[deg.]C at a final strand concentration of 8 [mu]M.
</P>
<P>[0037] Figure 6a illustrates stability of <ne id="WO2007038869.HC.class-names.238" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> to 10% fetal bovine serum (FBS) as monitored by polyacrylamide gel electrophoresis (time points: 0, 0.25, 0.5, 1, 2, 6, 24h) .
</P>
<P>[0038] Figures 6b and 6c illustrates stability curve of <ne id="WO2007038869.HC.class-names.239" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> to 10% FBS as monitored by polyacrylamide gel electrophoresis .
</P>
<P>[0039] Figures 7a and 7b illustrates nitrocellulose filter binding curves for <ne id="WO2007038869.HC.class-names.240" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> following exposure to bovine thrombin.
</P>
<P>[0040] Figure 8 illustrates CD spectra of dT2G4T2 and related sequences (PG17, 28, 19, 20, 21, 22, 23 &amp; 24) obtained in phosphate buffered saline (PBS <ne type="ONT" id="WO2007038869.HC.class-names.404" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>), 137 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.8" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>, 2.7 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.27" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, 1.5 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.40" epochem-id="EPOCHEM:NEW:FORMULA:132" name="KH2PO4" comment="" chebi-id="WO2007038869:547589" relevant="false">KH2PO4</ne>, 8 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.1" epochem-id="EPOCHEM:NEW:FORMULA:130" name="Na2HPO4" comment="" chebi-id="CHEBI:34683" relevant="false">Na2HPO4</ne>, pH 7.2 at 25&lt;0&gt;C; strand concentration: 20 [mu]M.
</P>
<P>[0041] Figure 9 illustrates temperature-dependent CD spectra for PG17, PG18, PG19 and PG20 and resulting Tm curves for each complex. The solvent is phosphate buffered saline (PBS <ne type="ONT" id="WO2007038869.HC.class-names.405" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>), 137 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.9" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>, 2.7 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.28" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, 1.5 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.41" epochem-id="EPOCHEM:NEW:FORMULA:132" name="KH2PO4" comment="" chebi-id="WO2007038869:547589" relevant="false">KH2PO4</ne>, 8 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.2" epochem-id="EPOCHEM:NEW:FORMULA:130" name="Na2HPO4" comment="" chebi-id="CHEBI:34683" relevant="false">Na2HPO4</ne>, pH 7.2 at 25[deg.]C; strand concentration: 20 [mu]M; 10 min equilibrium time was set at each temperature studied. The resulting Tn, curves were generated by plotting the maximum absorbance at 265 ran wavelength (normalized) vs temperature; the corresponding Tm data are shown in Table 2.
</P>
<P>[0042] Figure 10. Temperature-dependent CD spectra for PG24: phosphate buffered saline (PBS <ne type="ONT" id="WO2007038869.HC.class-names.406" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>), 137 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.10" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>, 2.7 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.29" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, 1.5 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.42" epochem-id="EPOCHEM:NEW:FORMULA:132" name="KH2PO4" comment="" chebi-id="WO2007038869:547589" relevant="false">KH2PO4</ne>, 8 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.3" epochem-id="EPOCHEM:NEW:FORMULA:130" name="Na2HPO4" comment="" chebi-id="CHEBI:34683" relevant="false">Na2HPO4</ne>, pH 7.2 at 25[deg.]C; strand concentration: 20 [mu]M; solutions were allowed to equilibrate for 10 min after each temperature change.
</P>
<P>[0043] Figure 11. CD spectra of dT4G4T4 and related sequences (PG25-28) : 10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.99" epochem-id="EPOCHEM:NEW:COMPOUND:1308" name="sodium phosphate" comment="" chebi-id="WO2007038869:679723" relevant="false">sodium phosphate</ne> <ne type="ONT" id="WO2007038869.HC.class-names.407" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>, 0.1 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.125" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007038869:318736" relevant="false">EDTA</ne>, pH 7 and 200 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.11" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>; strand concentration: 10 [mu]M.
</P>
<P>[0044] Figure 12a-e illustrates a: Tm profile of dT4G4T4 and related sequences (PG25-28) , whereas Figure 12b-e: illustrate the effect of heating and cooling process during thermal melting measurements at 10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.100" epochem-id="EPOCHEM:NEW:COMPOUND:1308" name="sodium phosphate" comment="" chebi-id="WO2007038869:679723" relevant="false">sodium phosphate</ne> <ne type="ONT" id="WO2007038869.HC.class-names.408" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>, 0.1 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.126" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007038869:318736" relevant="false">EDTA</ne>, pH 7 and 200 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.12" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>; strand concentration: 100 [mu]M.
Detailed Description
</P>
<P>[0045] This invention relates to modified <ne id="WO2007038869.HC.class-names.212" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">oligonucleotides</ne> that are capable of selectively binding to a protein target. In particular, <ne id="WO2007038869.HC.class-names.241" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> having short strands of DNA and modified <ne id="WO2007038869.HC.class-names.182" epochem-id="EPOCHEM:NEW:CLASS:624" name="arabinonucleic acids" comment="" chebi-id="WO2007038869:440906" relevant="false" type="CLASS">arabinonucleic acids</ne> is shown, in contrast to the common methods described above, which have concentrated on the use of linkers, hairpins and modified nucleoside derived from the naturally occurring units (i.e., DNA and RNA nucleotides) .
</P>
<P>[0046] This invention encompasses the characterization of a series of sugar modified nucleic acid ligands that bind thrombin. These nucleic acid ligands (or <ne id="WO2007038869.HC.class-names.242" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne>) contain arabinose modified nucleotides conferring improved characteristics on the ligand, such as improved folding (thermal stability, Tm) and stability against nucleases present in body fluid. The invention also encompasses the induction and stabilization of G-tetrads comprising arabinose <ne id="WO2007038869.HC.class-names.184" epochem-id="EPOCHEM:NEW:CLASS:17" name="sugars" comment="" chebi-id="WO2007038869:93805" relevant="false" type="CLASS">sugars</ne>. Preferably, the sugar modified nucleotides are 2'-deoxy-2'- fluoroarabinonucleotides (<ne id="WO2007038869.HC.class-names.340" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>) .
The method for generating the <ne id="WO2007038869.HC.class-names.341" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modified ligand necessitates the substitution of DNA bases in a known anti-thrombin <ne id="WO2007038869.HC.class-names.469" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> dGGTTGGTGTGGTTGG (15- nt) , anti-HIV <ne id="WO2007038869.HC.class-names.470" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> dTTGGGGTT (8-nt) and telomeric <ne id="WO2007038869.HC.class-names.272" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> dGGGGTTTTGGGG (12-nt) , for <ne id="WO2007038869.HC.class-names.342" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> residues. In all cases, folding was assayed using circular dichroism and UV melting experiments, whereas for dGGTTGGTGTGGTTGG, thrombin binding was determined using a nitrocellulose filter binding assay. Selective, specific and efficient binding of such <ne id="WO2007038869.HC.class-names.343" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modified nucleic acid ligands to thrombin is demonstrated. Previous studies with the anti-thrombin <ne id="WO2007038869.HC.class-names.471" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> dGGTTGGTGTGGTTGG have shown that replacing the native DNA bases by modified bases generally disrupts the <ne id="WO2007038869.HC.class-names.472" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> structure. The compounds disclosed here represent the first examples of <ne id="WO2007038869.HC.class-names.344" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modified <ne id="WO2007038869.HC.class-names.243" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> that bind thrombin effectively.
</P>
<P>[0047] This invention provides <ne id="WO2007038869.HC.class-names.345" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> nucleotides that are compatible with the structure and activity of the thrombin binding DNA <ne id="WO2007038869.HC.class-names.473" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>; in addition, it is shown that the <ne id="WO2007038869.HC.class-names.346" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modification can be effected without SELEX; rather, it involves incorporation of a sufficient number of <ne id="WO2007038869.HC.class-names.347" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> units
(via solid-phase chemical methods) to allow increased nuclease and thermal stability without significant loss of binding affinity for the target biomolecule. Unexpectedly, in some cases, target binding activity is improved over the known thrombin binding DNA <ne id="WO2007038869.HC.class-names.474" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>.
</P>
<P>[0048] The thermal stability of G-quadruplexes (G-tetrads) is also shown to be improved by inserting <ne id="WO2007038869.HC.class-names.348" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> residues within the <ne id="WO2007038869.HC.class-names.273" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> chain of the thrombin binding <ne id="WO2007038869.HC.class-names.475" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> 5'- dGGTTGGTGTGGTTGG, the anti-HIV <ne id="WO2007038869.HC.class-names.476" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> dT2G4T2 and the telomeric <ne id="WO2007038869.HC.class-names.274" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> dG4T4G4. Accordingly, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.87" epochem-id="EPOCHEM:NEW:COMPOUND:1731" name="2' -deoxy-2' -fluor[sigma]-[beta]-D- arabinoguanosine" comment="" chebi-id="WO2007038869:976364" relevant="false">2' -deoxy-2' -fluor[sigma]-[beta]-D- arabinoguanosine</ne> (araF-G) alone, or in combination with deoxyguanosine units, are capable of folding into a G-quartet structure. Based on these findings, the araF-G alone, or in combination with deoxyguanosine (dG) can be employed for stabilizing other G-quartet structures, including those of therapeutic interest described above, thereby enhancing their properties in vivo. As such, according to another broad aspect of the invention, <ne id="WO2007038869.HC.class-names.349" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-DNA <ne id="WO2007038869.HC.class-names.275" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> chimeras of G- quartet containing <ne id="WO2007038869.HC.class-names.244" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> are provided.
</P>
<P>[0049] A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of a modified nucleic acid of the invention may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the modified nucleic acid to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions .
</P>
<P>[0050] As used herein "pharmaceutically acceptable carrier" or "excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration. Alternatively, the carrier can be suitable for intravenous, intraperitoneal, intramuscular, sublingual or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
</P>
<P>[0051] Therapeutic compositions typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration. The carrier can be a solvent or dispersion medium containing, for example, water, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.88" epochem-id="EPOCHEM:COMPOUND:4765" name="ethanol" comment="" chebi-id="CHEBI:16236" relevant="false">ethanol</ne>, polyol (for example, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.89" epochem-id="EPOCHEM:COMPOUND:1821" name="glycerol" comment="" chebi-id="CHEBI:17754" relevant="false">glycerol</ne>, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.91" epochem-id="EPOCHEM:NEW:COMPOUND:25" name="propylene glycol" comment="" chebi-id="CHEBI:16997" relevant="false">propylene glycol</ne>, and liquid <ne type="CHEMICAL" id="WO2007038869.HC.substance-names.1" epochem-id="EPOCHEM:NEW:SUBSTANCE:2" name="polyethylene glycol" comment="" chebi-id="CHEBI:46793" relevant="false">polyethylene glycol</ne>, and the like) , and suitable mixtures thereof.
The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, <ne id="WO2007038869.HC.class-names.185" epochem-id="EPOCHEM:NEW:CLASS:17" name="sugars" comment="" chebi-id="WO2007038869:93805" relevant="false" type="CLASS">sugars</ne>, <ne id="WO2007038869.HC.class-names.183" epochem-id="EPOCHEM:NEW:CLASS:625" name="polyalcohols" comment="" chebi-id="WO2007038869:295932" relevant="false" type="CLASS">polyalcohols</ne> such as <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.92" epochem-id="EPOCHEM:COMPOUND:2429" name="mannitol" comment="" chebi-id="CHEBI:29864" relevant="false">mannitol</ne>, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.93" epochem-id="EPOCHEM:NEW:COMPOUND:990" name="sorbitol" comment="" chebi-id="CHEBI:30911" relevant="false">sorbitol</ne>, or <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.94" epochem-id="EPOCHEM:COMPOUND:6837" name="sodium chloride" comment="" chebi-id="CHEBI:26710" relevant="false">sodium chloride</ne> in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.95" epochem-id="EPOCHEM:NEW:COMPOUND:1732" name="monostearate" comment="" chebi-id="WO2007038869:906230" relevant="false">monostearate</ne> salts and gelatin. Moreover, an <ne id="WO2007038869.HC.class-names.276" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> of the invention can be administered in a time release formulation, for example in a composition which includes a slow release polymer. The modified <ne id="WO2007038869.HC.class-names.277" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> can be prepared with carriers that will protect the modified <ne id="WO2007038869.HC.class-names.278" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.96" epochem-id="EPOCHEM:NEW:COMPOUND:1733" name="ethylene vinyl acetate" comment="" chebi-id="WO2007038869:440634" relevant="false">ethylene vinyl acetate</ne>, <ne type="CHEMICAL" id="WO2007038869.HC.substance-names.2" epochem-id="EPOCHEM:NEW:SUBSTANCE:162" name="polyanhydrides" comment="" chebi-id="WO2007038869:975293" relevant="false">polyanhydrides</ne>, <ne type="CHEMICAL" id="WO2007038869.HC.substance-names.3" epochem-id="EPOCHEM:NEW:SUBSTANCE:163" name="polyglycolic acid" comment="" chebi-id="WO2007038869:757660" relevant="false">polyglycolic acid</ne>, collagen, <ne type="CHEMICAL" id="WO2007038869.HC.substance-names.4" epochem-id="EPOCHEM:NEW:SUBSTANCE:164" name="polyorthoesters" comment="" chebi-id="WO2007038869:364348" relevant="false">polyorthoesters</ne>, <ne type="CHEMICAL" id="WO2007038869.HC.substance-names.5" epochem-id="EPOCHEM:NEW:SUBSTANCE:165" name="polylactic acid" comment="" chebi-id="WO2007038869:987003" relevant="false">polylactic acid</ne> and polylactic, polyglycolic copolymers (PLG) . Many methods for the preparation of such formulations are patented or generally known to those skilled in the art.
</P>
<P>[0052] Sterile injectable solutions can be prepared by incorporating an active compound, such as an <ne id="WO2007038869.HC.class-names.279" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> of the invention, in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered solution thereof. In accordance with an alternative aspect of the invention, an <ne id="WO2007038869.HC.class-names.280" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> of the invention may be formulated with one or more additional compounds that enhance its solubility.
</P>
<P>[0053] Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. In the claims, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to" .
</P>
<P>[0054] The following examples are illustrative of various aspects of the invention, and do not limit the broad aspects of the invention as disclosed herein.
Example 1: Chemical synthesis of <ne id="WO2007038869.HC.class-names.213" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">oligonucleotides</ne>
</P>
<P>[0055] The sequence and composition of the oligomers prepared in this study are shown in Table 1 and Table 2. <ne id="WO2007038869.HC.class-names.350" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modified <ne id="WO2007038869.HC.class-names.477" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> syntheses were carried out on a 1/[Lambda][Pi]OI scale on an Applied Biosystems (ABI) 3400A synthesizer using the standard j3-cyanoethylphosphoramidite chemistry according to published protocols [E. Viazovkina, M.M. Mangos, M.I. Elzagheid, and M.J. Damha (2002) Current Protocols in Nucleic Acid Chemistry, Unit 4.15)] . The final concentrations of the monomers were 0.10 M for <ne id="WO2007038869.HC.class-names.186" epochem-id="EPOCHEM:NEW:CLASS:626" name="2' -deoxyribonucleoside phosphoramidites" comment="" chebi-id="WO2007038869:780329" relevant="false" type="CLASS">2' -deoxyribonucleoside phosphoramidites</ne> and 0.125 M for the ara F <ne id="WO2007038869.HC.class-names.189" epochem-id="EPOCHEM:NEW:CLASS:627" name="phosphoramidites" comment="" chebi-id="WO2007038869:391438" relevant="false" type="CLASS">phosphoramidites</ne> . The coupling time was extended to 150 seconds for the <ne id="WO2007038869.HC.class-names.187" epochem-id="EPOCHEM:NEW:CLASS:626" name="2' -deoxyribonucleoside phosphoramidites" comment="" chebi-id="WO2007038869:780329" relevant="false" type="CLASS">2'- deoxyribonucleoside phosphoramidites</ne> (dC, dG) , 15 min for the modified araF <ne id="WO2007038869.HC.class-names.191" epochem-id="EPOCHEM:NEW:CLASS:324" name="nucleosides" comment="" chebi-id="CHEBI:33838" relevant="false" type="CLASS">nucleosides</ne>. These conditions gave about 99% average coupling yields and usually over 100 optically density units (A260) in yield. <ne id="WO2007038869.HC.class-names.245" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">Aptamers</ne> were purified by anion exchange HPLC and kept at -20&lt;0&gt;C for further use.
Example 2. UV Thermal Denaturation Studies of Thrombin Binding
<ne id="WO2007038869.HC.class-names.246" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">Aptamers</ne> .
</P>
<P>[0056] UV thermal denaturation data were obtained on a Varian CARY 1 spectrophotometer equipped with a Peltier temperature controller. <ne id="WO2007038869.HC.class-names.247" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">Aptamers</ne> were dissolved in Tm <ne type="ONT" id="WO2007038869.HC.class-names.409" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> (10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.113" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>, pH 6.8 with and without 25mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.30" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>) at a final concentration of 8 [mu]M. <ne id="WO2007038869.HC.class-names.248" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">Aptamers</ne> were annealed in Tn, <ne type="ONT" id="WO2007038869.HC.class-names.410" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> at 80&lt;0&gt;C for 10 minutes, naturally cooled down to room temperature and refrigerated (4[deg.]C) overnight before measurements. The annealed samples were transferred to pre-chilled Hellma QS- 1.000 (Cat #114) quartz celled, sealed with a Teflon-wrapped stopper and degassed by placing them in an ultrasound bath for 1 min. Extinction coefficients were obtained from the following internet site
(http: //paris .chem.yale.edu/extinct .html) and <ne id="WO2007038869.HC.class-names.351" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modified <ne id="WO2007038869.HC.class-names.249" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> were assume to have the same extinction coefficient as the regular DNA <ne id="WO2007038869.HC.class-names.478" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>. Denaturation curves were acquired at 295 nm at a rate of heating of 0.5[deg.]C/min. The data were analyzed with the software provided by Varian Canada and converted to Microsoft Excel . Absorbance versus temperature profiles were adapted for a unimolecular transition. Slopping baselines were achieved by constructing liner least-squares lines for associated and dissociated parts and extrapolating to both ends of the melting curve. Consequently, a plot of the fractions of single strands in the G-qudruplex state ([alpha]) versus temperature was constructed and used to calculate the Tm value by interpolating to Ct= 0.5 (Figures 2a and 2b) .
</P>
<P>[0057] Tm concentration dependence studies were also conducted in the same way at 295nm using <ne id="WO2007038869.HC.class-names.250" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> with different concentrations ranging from 4 to 76[mu]M. Starna quartz cells (Starna Cells, Inc., Cat. # 1-Q-l) with lmm path length were used to reduce the amount of <ne id="WO2007038869.HC.class-names.251" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> required (Figure 3) . The data shows that incorporation of <ne id="WO2007038869.HC.class-names.352" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> residues into the <ne id="WO2007038869.HC.class-names.281" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> backbone leads to an increase in the melting temperature of the complex formed ([Delta]Tm up to +3[deg.]C/<ne id="WO2007038869.HC.class-names.353" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modification) .
The structure is stabilized by potassium ion as shown in Figure 2, consistent with the formation of a unimolecular <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.71" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> structure (see Example 3) . The unimolecularity of folding was ascertained for some of the sequences by measuring the Tn, value at varying <ne id="WO2007038869.HC.class-names.282" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> concentrations (Figure 3), and by obtaining heating and cooling Tm curves (Figure 4) . Unimolecular folding is characterized by a Tm value that is independent of <ne id="WO2007038869.HC.class-names.283" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> concentration, e.g. AP34, AP35, APT-13 and APT-F14, but not AP32 and AP33 (Figure 3), and by fast kinetics of melting and re-annealing, e.g. AP34, AP35, APT-13 and APT-F14, but not AP32 and AP33 (Figure 4) . Note that all Type II <ne id="WO2007038869.HC.class-names.252" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> (as assessed by CD; see Example 3) displayed identical heating and cooling Tm curves (Figure 4) , consistent with the fast kinetics of folding/unfolding that characterizes the unimolecular structure shown in Figure 1.
Example 3. Circular Dichroism (CD) Spectra of Thrombin Binding
<ne id="WO2007038869.HC.class-names.253" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">Aptamers</ne> . [0058] CD spectra (200-320 nm) were collected on a Jasco J- 710 spectropolarimeter at a rate of lOOnm/min using fused quartz cells (Hellma, 165-QS) . Measurements were carried out in Tn, <ne type="ONT" id="WO2007038869.HC.class-names.411" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> (10 [pi]iM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.114" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>, pH 6.8 with and without 25mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.31" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>) at a concentration of 8[mu]M. Temperature was controlled by an internal circulating bath (VWR Scientific) at constant temperature (15&lt;0&gt;C) . The data were processed on a PC computer using J-700 Windows software supplied by the manufacturer (JASCO, Inc.).
To facilitate comparisons, the CD spectra were background subtracted, smoothed and were corrected for concentration so that molar ellipticities could be obtained (Figures 5a-c) . These experiments assess the impact of the <ne id="WO2007038869.HC.class-names.354" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modification on the <ne id="WO2007038869.HC.class-names.479" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> structures. CD spectra of <ne id="WO2007038869.HC.class-names.254" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> revealed the formation of two different <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.72" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> structures, referred to as "I" and "II" (Table 1 &amp; Figure 5) . The "II" type CD signature corresponds to the well- characterized, potassium (K+) induced, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.73" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> structure adopted by the all-DNA <ne id="WO2007038869.HC.class-names.480" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> dGGTTGGTGTGGTTGG. In fact, only type- II <ne id="WO2007038869.HC.class-names.255" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> showed an affinity to the target protein (human thrombin), and not all type- II <ne id="WO2007038869.HC.class-names.256" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> bound to thrombin (Table 1 &amp; Figure 7) .
For example, the type-II <ne id="WO2007038869.HC.class-names.257" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> AP-F13 and AP-F14 were found to bind to human thrombin with a higher affinity relative to the all-DNA <ne id="WO2007038869.HC.class-names.481" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>, whereas APT-Fl and F3 bound weakly, if at all to thrombin. Type II <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.74" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> structures were also found to be very stable particularly when DNA-G (dG) residues with "anti" glycosidic bonds are replaced by <ne id="WO2007038869.HC.class-names.355" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-G. The stabilization of G (anti) residues over G (syn) arises from the steric interactions the 2 '-<ne type="LIGAND" id="WO2007038869.HC.ligand-names.65" epochem-id="EPOCHEM:NEW:LIGAND:352" name="fluorine" comment="" chebi-id="CHEBI:24061" relevant="false">fluorine</ne> atom and the G base in the syn conformation. As a result <ne id="WO2007038869.HC.class-names.356" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-G residues induce and stabilize Type II G-tetrads containing anti G residues. If dG (syn) positions are replaced by <ne id="WO2007038869.HC.class-names.357" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-G residues, the <ne id="WO2007038869.HC.class-names.482" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> switches to the type "I" <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.75" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne>, in which all guanines likely adopt the anti conformation (Table 1 and Figure 5) . In these cases, binding to thrombin was lost, consistent the the exquisite specificity of thrombin to type-II DNA and type-II <ne id="WO2007038869.HC.class-names.358" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-DNA structures. The same principles applied to the type-II telomeric <ne id="WO2007038869.HC.class-names.284" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> series derived from dGGGGTTTTGGGG (Example 6) .
Example 4. Nuclease Stability Assay
</P>
<P>[0059] Nuclease stability of <ne id="WO2007038869.HC.class-names.258" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> was conducted in 10% Fetal Bovine Serum (FBS, Wisent Inc., Cat. #080150) diluted with multicell Dulbeco's Modification Eagle's Medium (DMEM, Wisent Inc., Cat. #319005-CL) at 37[deg.]C. A single strand DNA (ssDNA) 23mer (P-8) which has not capacity to form G- quadruplex was used as a control . About 8[mu]mol stock solution of <ne id="WO2007038869.HC.class-names.259" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> and ssDNA control (-1.2 O.D.U) was lyophilized to dryness and then incubated with 300[mu]l 10% FBS at 37[deg.]C.
At 0, 0.25, 0.5, 1, 2, 6 and 24h, 50[mu]l of samples were collected and stored at -20&lt;0&gt;C for at least 20min. The samples were lyophilized to dryness and added lO[mu]l gel loading <ne type="ONT" id="WO2007038869.HC.class-names.412" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> and lO[mu]l autoclaved water. lO[mu]l of the mixture was used for polyacrylamide gel electrophoresis (PAGE) which was carried out at room temperature using 20% polyacrylamide gel in 0.5xTBE <ne type="ONT" id="WO2007038869.HC.class-names.413" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> (<ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.115" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>-<ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.124" epochem-id="EPOCHEM:COMPOUND:1359" name="borate" comment="" chebi-id="CHEBI:22908" relevant="false">borate</ne>-<ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.127" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007038869:318736" relevant="false">EDTA</ne>) . Degradation pattern on gels was visualized by Stains-All (Bio-Rad) according to manufacturer's protocol. The solution was made of <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.106" epochem-id="EPOCHEM:NEW:COMPOUND:1735" name="l-Ethyl-2- [3- (1-ethylnaphtho [1, 2-d] thiazolin-2-ylidene) -2- methylpropenyl] naphtho [1, 2-d] thiazolium bromide" comment="" chebi-id="WO2007038869:667076" relevant="false">l-Ethyl-2- [3- (1-ethylnaphtho [1, 2-d] thiazolin-2-ylidene) -2- methylpropenyl] naphtho [1, 2-d] thiazolium bromide</ne> (Figures 6a, 6b and 6c) . The data shows that nuclease stability can be dependent on one or both the position and number of <ne id="WO2007038869.HC.class-names.359" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> residues within the <ne id="WO2007038869.HC.class-names.285" epochem-id="EPOCHEM:NEW:CLASS:882" name="oligonucleotide" comment="" chebi-id="WO2007038869:85294" relevant="false" type="CLASS">oligonucleotide</ne> backbone, and that the <ne id="WO2007038869.HC.class-names.360" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> residues confer significant stability against hydrolytic nucleases. For example, the nuclease stability of APT-F13 and F14 is enhanced over the native APT-35 structure by a factor of 4-7.
Example 5. 5' -End Labeling of Synthetic <ne id="WO2007038869.HC.class-names.214" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">Oligonucleotides</ne> and Filter Binding Assay [0060] <ne id="WO2007038869.HC.class-names.260" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">Aptamers</ne> were radioactively labeled at the 5'- <ne type="LIGAND" id="WO2007038869.HC.ligand-names.26" epochem-id="EPOCHEM:NEW:LIGAND:1" name="hydroxyl" comment="" chebi-id="CHEBI:29191" relevant="false">hydroxyl</ne> terminus with a radioactive <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.107" epochem-id="EPOCHEM:NEW:COMPOUND:1736" name="phosphorous" comment="" chebi-id="WO2007038869:334999" relevant="false">phosphorous</ne> probe and the enzyme T4 polynucleotide kinase (T4 PNK) according to the manufacture's specifications (MBI Fermentas Life Sciences, Burlington, ON) .
Incorporation of the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.121" epochem-id="EPOCHEM:NEW:COMPOUND:2002" name="&lt;32&gt;P" comment="" chebi-id="CHEBI:37972" relevant="false">&lt;32&gt;P</ne> label was accomplished in reaction mixtures consisting of DNA <ne id="WO2007038869.HC.class-names.261" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> substrate (lOOpmol) , 2[mu]l lOxreaction <ne type="ONT" id="WO2007038869.HC.class-names.414" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> (<ne type="ONT" id="WO2007038869.HC.class-names.415" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">Buffer</ne> A for forward reaction: 50OmM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.116" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>-<ne type="FORMULA" id="WO2007038869.HC.formula-names.52" epochem-id="EPOCHEM:NEW:FORMULA:106" name="HCl" comment="" chebi-id="CHEBI:17883" relevant="false">HCl</ne>, pH 7.6 at 25[deg.]C, 10OmM <ne type="FORMULA" id="WO2007038869.HC.formula-names.47" epochem-id="EPOCHEM:NEW:FORMULA:133" name="MgCl2" comment="" chebi-id="CHEBI:6636" relevant="false">MgCl2</ne>, 5OmM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.134" epochem-id="EPOCHEM:NEW:COMPOUND:1965" name="DTT" comment="" chebi-id="WO2007038869:300876" relevant="false">DTT</ne>, ImM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.97" epochem-id="EPOCHEM:COMPOUND:3732" name="spermidine" comment="" chebi-id="CHEBI:16610" relevant="false">spermidine</ne> and ImM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.128" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007038869:318736" relevant="false">EDTA</ne>) , l[mu]l T4 PNK enzyme solution (lOU/l[mu]l in a solution of 2OmM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.117" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>-<ne type="FORMULA" id="WO2007038869.HC.formula-names.53" epochem-id="EPOCHEM:NEW:FORMULA:106" name="HCl" comment="" chebi-id="CHEBI:17883" relevant="false">HCl</ne>, pH 7.5, 25mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.32" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, 0.ImM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.129" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007038869:318736" relevant="false">EDTA</ne>, 2mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.135" epochem-id="EPOCHEM:NEW:COMPOUND:1965" name="DTT" comment="" chebi-id="WO2007038869:300876" relevant="false">DTT</ne> and 50% <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.90" epochem-id="EPOCHEM:COMPOUND:1821" name="glycerol" comment="" chebi-id="CHEBI:17754" relevant="false">glycerol</ne>), 6[mu]l [[gamma]-<ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.122" epochem-id="EPOCHEM:NEW:COMPOUND:2002" name="&lt;32&gt;P" comment="" chebi-id="CHEBI:37972" relevant="false">&lt;32&gt;P</ne>] -<ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.136" epochem-id="EPOCHEM:COMPOUND:2720" name="ATP" comment="" chebi-id="WO2007038869:945144" relevant="false">ATP</ne> solution (6000Ci/mmol, lOmCi/ml; Amersham Biosciences, Inc.) and autoclaved sterile water to a final volume of 20[mu]l. The reaction mixture was incubated for about 45-60min at 37[deg.]C, followed by a second incubation for lOmin at 95[deg.]C to heat denature and deactivate the kinase enzyme. The solution was purified according to a standard protocol [Carriero, S. and Damha, M.J. (2003) Nucleic Acids Res. 31: 6157-6167] and the isolated yield of <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.123" epochem-id="EPOCHEM:NEW:COMPOUND:2002" name="&lt;32&gt;P" comment="" chebi-id="CHEBI:37972" relevant="false">&lt;32&gt;P</ne>-5'-DNA following gel extraction averages 50%. The pure labeled samples were kept at -20&lt;0&gt;C for future use.
</P>
<P>[0061] Nitrocellulose filter binding is to confirm if there is binding between selected <ne id="WO2007038869.HC.class-names.262" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> and thrombin. Constant amount of labeled <ne id="WO2007038869.HC.class-names.263" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> (1.25 pmol) were heated to 95&lt;0&gt;C for 5 minutes in the binding <ne type="ONT" id="WO2007038869.HC.class-names.416" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> (<ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.118" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>-Ac, pH 7.4, 14OmM <ne type="FORMULA" id="WO2007038869.HC.formula-names.13" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>, 5mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.33" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, ImM <ne type="FORMULA" id="WO2007038869.HC.formula-names.50" epochem-id="EPOCHEM:NEW:FORMULA:134" name="CaCl2" comment="" chebi-id="CHEBI:3312" relevant="false">CaCl2</ne>, ImM <ne type="FORMULA" id="WO2007038869.HC.formula-names.48" epochem-id="EPOCHEM:NEW:FORMULA:133" name="MgCl2" comment="" chebi-id="CHEBI:6636" relevant="false">MgCl2</ne>) and immediately set on ice for 5 minutes before binding to increasing concentrations of thrombin protease (Amersham Biosciences, Inc.) ranging from 6- 1380 nM in the binding <ne type="ONT" id="WO2007038869.HC.class-names.417" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> at 37[deg.]C in a final volume of 20 [mu]l for 30minutes.
Mixtures were filtered through a nitrocellulose filter (13 mm Millipore, HAWP, 0.45 [mu]m) pre- wetted with binding <ne type="ONT" id="WO2007038869.HC.class-names.418" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> in a Millipore filter binding apparatus, and immediately rinsed with 600 [mu]l ice cold washing <ne type="ONT" id="WO2007038869.HC.class-names.419" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> (<ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.119" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>-Ac, pH 7.4, 14OmM <ne type="FORMULA" id="WO2007038869.HC.formula-names.14" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>, 5mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.34" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, ImM <ne type="FORMULA" id="WO2007038869.HC.formula-names.51" epochem-id="EPOCHEM:NEW:FORMULA:134" name="CaCl2" comment="" chebi-id="CHEBI:3312" relevant="false">CaCl2</ne>, ImM <ne type="FORMULA" id="WO2007038869.HC.formula-names.49" epochem-id="EPOCHEM:NEW:FORMULA:133" name="MgCl2" comment="" chebi-id="CHEBI:6636" relevant="false">MgCl2</ne>, 1% <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.98" epochem-id="EPOCHEM:NEW:COMPOUND:1734" name="sodium pyrophosphate" comment="" chebi-id="WO2007038869:550723" relevant="false">sodium pyrophosphate</ne> (w/v) ) , then the filter was air dried and the bound <ne id="WO2007038869.HC.class-names.483" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> quantified by scintillation counting. The binding percentage (%) was calculated by the subtraction of counts in the miscrotube and background, i[zeta]j could be roughly determined by least squares fit of the data points to a binding equation that assumes a simple bimolecular RNA-thrombin interaction. The binding curves for various <ne id="WO2007038869.HC.class-names.264" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne>, including controls, are shown in Figures 7a and 7b, whereas binding data are given on Table 1. The data shows that binding of two (APT-F13 and F14) of the <ne id="WO2007038869.HC.class-names.265" epochem-id="EPOCHEM:NEW:CLASS:881" name="aptamers" comment="" chebi-id="WO2007038869:556696" relevant="false" type="CLASS">aptamers</ne> tested is quantitative and improved over the native DNA <ne id="WO2007038869.HC.class-names.484" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> AP35. These compounds also adopt the required <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.76" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> structure recognized by thrombin ("Type II" structure), as assessed by CD spectroscopy. Furthermore, the nuclease stability of APT- F13 and F14 is enhanced over APT-35 by a factor of 4-7.
Example 6. Circular Dichroism (CD) Spectroscopy and Thermal
Denaturation Studies Reveals <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.77" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-Tetrad</ne> Formation and
Stabilization by Arabinose-modified <ne id="WO2007038869.HC.class-names.215" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">Oligonucleotides</ne>
(dTTGGGGTT and dGGGGTTTTGGGG) .
</P>
<P>[0062] UV thermal denaturation data were obtained on a Varian CARY 1 spectrophotometer equipped with a Peltier temperature controller. dT2G4T2 and related sequences (PG17-24) were dissolved in phosphate buffered saline (PBS <ne type="ONT" id="WO2007038869.HC.class-names.420" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>, pH 7.2), 137 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.15" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>, 2.7 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.35" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, 1.5 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.43" epochem-id="EPOCHEM:NEW:FORMULA:132" name="KH2PO4" comment="" chebi-id="WO2007038869:547589" relevant="false">KH2PO4</ne>, 8 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.4" epochem-id="EPOCHEM:NEW:FORMULA:130" name="Na2HPO4" comment="" chebi-id="CHEBI:34683" relevant="false">Na2HPO4</ne> at a final concentration of 20 [mu]M. dG4T4G4 and related sequences (PG25-28) were dissolved in 10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.101" epochem-id="EPOCHEM:NEW:COMPOUND:1308" name="sodium phosphate" comment="" chebi-id="WO2007038869:679723" relevant="false">sodium phosphate</ne> <ne type="ONT" id="WO2007038869.HC.class-names.421" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>, pH 7, 0.1 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.130" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007038869:318736" relevant="false">EDTA</ne>, and 200 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.16" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>; at a final concentration of 100 [mu]M. All samples were annealed at 95[deg.]C for 5 minutes, naturally cooled down to room temperature and refrigerated (4[deg.]C) overnight before measurements.
The annealed samples were transferred to pre-chilled Hellma QS- 1.000 (Cat #114) quartz celled, sealed with a Teflon-wrapped stopper and degassed by placing them in an ultrasound bath for 1 min. Extinction coefficients were obtained from the following internet site (http : //www. idtdna . com/analyzer/Applications/OligoAnalyzer/ ) and <ne id="WO2007038869.HC.class-names.361" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modified sequences were assumed to have the same extinction coefficient as the regular DNA sequence. Denaturation curves were acquired at 260 nm for dT2G4T2 and related sequences (PG17-24) , 295 nm for dG4T4G4 and related sequences (PG25-28) at a heating/cooling rate of 0.5[deg.]C/min starting from 20&lt;0&gt;C to 90&lt;0&gt;C (for PG17-24) or 40&lt;0&gt;C to 98[deg.]C (for PG25-28) . The data were analyzed with the software provided by Varian Canada and converted to Microsoft Excel (Table 2) .
</P>
<P>[0063] CD spectra (220-320 nm) were collected on a Jasco J- 710 spectropolarimeter at a rate of 100nm/min using fused quartz cells (Hellma, 165-QS) . Measurements were carried out in either PBS <ne type="ONT" id="WO2007038869.HC.class-names.422" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> for dT2G4T2 and related sequences PG17-24 (pH 7.2, 137 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.17" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>, 2.7 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.36" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, 1.5 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.44" epochem-id="EPOCHEM:NEW:FORMULA:132" name="KH2PO4" comment="" chebi-id="WO2007038869:547589" relevant="false">KH2PO4</ne>, 8 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.5" epochem-id="EPOCHEM:NEW:FORMULA:130" name="Na2HPO4" comment="" chebi-id="CHEBI:34683" relevant="false">Na2HPO4</ne>) at a final concentration of 20 [mu]M, or in <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.102" epochem-id="EPOCHEM:NEW:COMPOUND:1308" name="sodium phosphate" comment="" chebi-id="WO2007038869:679723" relevant="false">sodium phosphate</ne> <ne type="ONT" id="WO2007038869.HC.class-names.423" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> for dG4T4G4 and related sequences PG25-28 (10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.103" epochem-id="EPOCHEM:NEW:COMPOUND:1308" name="sodium phosphate" comment="" chebi-id="WO2007038869:679723" relevant="false">sodium phosphate</ne> <ne type="ONT" id="WO2007038869.HC.class-names.424" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>, pH 7, 0.1 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.131" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007038869:318736" relevant="false">EDTA</ne>, and 200 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.18" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>) at a final concentration of 100 [mu]M. Temperature was controlled by an internal circulating bath (VWR Scientific) at constant temperature (20&lt;0&gt;C) . The data were processed on a PC computer using J- 700 Windows software supplied by the manufacturer (JASCO, Inc.). To facilitate comparisons, the CD spectra were background subtracted, smoothed and were corrected for concentration so that molar ellipticities could be obtained.
</P>
<P>[0064] These above experiments assess the impact of the <ne id="WO2007038869.HC.class-names.362" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modification on the G-quartet structures. The <ne id="WO2007038869.HC.class-names.176" epochem-id="EPOCHEM:NEW:CLASS:621" name="oligomer" comment="" chebi-id="WO2007038869:267706" relevant="false" type="CLASS">oligomer</ne> dT2G4T2, is known to adopt a structure in which all of the G residues are in the anti conformation. As a result, a "Type I" signature characterizes this <ne id="WO2007038869.HC.class-names.485" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> (Table 2 and Figures 8 &amp; 9) . Tm profiles were obtained by plotting the maximum molar ellipticities versus temperature (Figure 10) . Compared with the controls PG17 (PO-DNA) and PG18 (PS-DNA) , <ne id="WO2007038869.HC.class-names.363" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> modified sequences PGl9 and PG20 showed much increased molar ellipticities indicating a better <ne id="WO2007038869.HC.class-names.398" epochem-id="EPOCHEM:NEW:CLASS:896" name="guanine" comment="" chebi-id="CHEBI:16235" relevant="false" type="CLASS">guanine</ne>-<ne id="WO2007038869.HC.class-names.399" epochem-id="EPOCHEM:NEW:CLASS:896" name="guanine" comment="" chebi-id="CHEBI:16235" relevant="false" type="CLASS">guanine</ne> interactions within the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.78" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> structure. Tm profiles (Figure 9) obtained by temperature-dependent CD spectra, clearly confirmed the significant thermal stabilization provided by the <ne id="WO2007038869.HC.class-names.364" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-G units (PG-18, 19 Sc 20; Table 2).
</P>
<P>[0065] The same principles applied to the telomeric series derived from dG4T4G4 (Table 2, and Figures 11 &amp; 12) . When the dG (anti) residues were replaced by <ne id="WO2007038869.HC.class-names.365" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> G residues, a modest thermal stabilization of the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.79" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> structure resulted without disruption of the 3 -dimensional structure (Table 2, and Figures 11 &amp; 12) . When the dG (syn) residues were replaced, a remarkable increase in thermal stabilization of the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.80" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> structure resulted (up to 25 degrees; Table 2) , with a concomitant type II-to-type I conformational change induced by the <ne id="WO2007038869.HC.class-names.366" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> G (anti) residues (Figure 11) .
</P>
<P>[0066] All references cited are incorporated by reference herein. Although preferred embodiments of the invention have been described herein, it will be understood by those skilled in the art that variations may be made thereto without departing from the spirit of the invention or the scope of the appended claims .
Table 1. Sequences, CD and Tm data of <ne id="WO2007038869.HC.class-names.216" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">Oligonucleotides</ne>
SEQ Typ
Name ID Type Sequence* e Kd No. II OaM) &lt;d &gt; &lt;1&gt; CD&lt;0&gt; )'Y,
AP32 1 All <ne id="WO2007038869.HC.class-names.367" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> 5' -GG-TT-GG-TGT-GG-TT- 54.1 - GG-3' 500 &gt;24
AP33 2 G- 5' -GG-tt-GG-tgt-GG-tt- 50.2 4.0
<ne id="WO2007038869.HC.class-names.368" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>/DNA GG-3' Q A Dc nU
AP34 3 G- 5' -gg-TT-gg-TGT-gg-TT- 56.3 + 5.9
DNA/<ne id="WO2007038869.HC.class-names.369" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> gg-3'
AP35 4 All DNA 5' -gg-tt-gg-tgt-gg-tt- 47.4 + o"\ n 0.5 gg-3'
APT- 5 <ne id="WO2007038869.HC.class-names.370" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> G- 5' -gG-tt-gG-tgt-gG-tt- 53.3 + 4.8
Fl anti gG-3'
APT- g <ne id="WO2007038869.HC.class-names.371" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> G- 5' -Gg-tt-Gg-tgt-Gg-tt- 45.4 &lt;-&gt;&gt;7nn 0.8
F2 syn Gg-3'
<ne id="WO2007038869.HC.class-names.372" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> G- 5' -gG-TT-gG-TGT-gG-TT-
Air J. - 61.6 + 9.4
</P>
<P>7 a[pi]ti &amp; T- gG-3' 500 c 3 loop
<ne id="WO2007038869.HC.class-names.373" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> G- 5' -Gg-TT-Gg-TGT-Gg-TT-
APT- 48.5 0.6
</P>
<P>8 syn &amp; T- Gg-3' F4 &gt;700 loop
</P>
<P>57.1 + inn 2.8
</P>
<P>51.2 + o c; n 2.7
</P>
<P>56.6 + 5.1
</P>
<P>59.1 + 3.5
JXU
</P>
<P>51.0 + 3.4
OO
</P>
<P>50.6 + 2
</P>
<P>40
EMI27.1
P-8 15 ssDNA 5'-gtc tct tgt gtg act NA NA NC 0.5 control ctg gta ac-3'
Hl 16 Hairpin 5'-GGAC (UUCG) GUCC-3' NA NA NC NA control &lt;a&gt; Capital and bold letter: <ne id="WO2007038869.HC.class-names.374" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>; Small letter: dna; Capital:
RMA&lt;'&gt; &lt; b&gt; NA: not applicable
"Type II" CD refers to a CD spectrum with positive band at ~ 295 nm and a negative band at ~ 260 nm, which indicates a alternative G-anti and G-syn conformation in the G-guartet. CD was measured in a <ne type="ONT" id="WO2007038869.HC.class-names.425" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne> consisting of 10 rtiM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.120" epochem-id="EPOCHEM:NEW:COMPOUND:2001" name="Tris" comment="" chebi-id="CHEBI:9754" relevant="false">Tris</ne>, 25mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.37" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, pH 6.8. &lt;d&gt; Kd was roughly estimated from the thrombin concentration (nM) necessary to achieve 50% of the maximum binding to the <ne id="WO2007038869.HC.class-names.486" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne>; NC: not calculated. Seq.
Code ID Type Sequence* CD Type ,&lt;1&gt;b,c [tau]m (Ar1n) NO. CO &lt;d&gt;-" dTTGGGGTT and related sequences
PG17 17 All PO- 5" -PO-tt-gggg-tt-3 ' I 66
DNA
All PS- 73.5&lt;[pound]&gt;
PG18 18 5' -PS-tt-gggg-tt-3 &lt;r&gt; I
DNA 74 (+8)
All PS-
PGl9 19 5 ' -PS-TT-GGGG-TT-3 ' I 83 (+17)
<ne id="WO2007038869.HC.class-names.375" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>
All <ne id="WO2007038869.HC.class-names.376" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-
PG20 20 5 ' -PS-tt-GGGG-tt-3 ' I 87 (+21)
G
All <ne id="WO2007038869.HC.class-names.377" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-
PG21 21 5 ' -PS-TT-gggg-TT-3 ' I n.d.&lt;9&gt;
T
PG22 22 2x <ne id="WO2007038869.HC.class-names.378" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-G 5 ' -PS-tt-GgGg-tt-3 ' I n.d.
PG23 23 2x <ne id="WO2007038869.HC.class-names.379" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-G 5' -PS-tt-gGgG-tt-3 ' I n.d.
PG24 24 2x <ne id="WO2007038869.HC.class-names.380" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>-G 5' -PS-tt-GggG-tt-3 ' I n.d. dGGGGI 7TTTi
All PO- 65&lt;h&gt;
PG25 2 -Z5b 5 ' -PO-gggg-tttt-gggg-3 ' II
DNA 64.4
All PO-
PG26 2 Z6b 5 ' -PO-GGGG-TTTT-GGGG-3 ' I -90 (+25.
<ne id="WO2007038869.HC.class-names.381" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne> 6)
PG27 27 G-syn 5 ' -PO-GgGg-tttt-GgGg-3 ' I 72.5 ( +8. 1)
PG28 28 G-anti 5 ' -PO-gGgG-tttt-gGgG-3 ' II 66.2 ( +1. 8)
Table 2. Sequences, CD and T[alpha] data of <ne id="WO2007038869.HC.class-names.217" epochem-id="EPOCHEM:NEW:CLASS:572" name="oligonucleotides" comment="" chebi-id="WO2007038869:942497" relevant="false" type="CLASS">oligonucleotides</ne>
&lt;a&gt;Small letter: dna; Capital and bold letter: <ne id="WO2007038869.HC.class-names.382" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>; PO: phosphate linkage; PS: <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.52" epochem-id="EPOCHEM:NEW:COMPOUND:1727" name="phosphorothioate" comment="" chebi-id="WO2007038869:297068" relevant="false">phosphorothioate</ne> linkage.
&lt;b&gt;CD type I refers to a positive CD band at ~265 nm and a negative band at - 240; CD type II refers to a positive band at - 295 nm and a negative band at- ~ 260 nm [Williamson, J.R. (1994) G-Quartet Structures in Telomeric DNA. Annu. Rev. Biophys. Biomol. Struct. 23^: 703-730].
&lt;c&gt;dT2G4T2 and related sequences (PGl7-24) : phosphate buffered saline (PBS <ne type="ONT" id="WO2007038869.HC.class-names.426" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>, pH 7.2 at 25[deg.]C) , 137 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.19" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>, 2.7 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.38" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, 1.5 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.45" epochem-id="EPOCHEM:NEW:FORMULA:132" name="KH2PO4" comment="" chebi-id="WO2007038869:547589" relevant="false">KH2PO4</ne>, 8 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.6" epochem-id="EPOCHEM:NEW:FORMULA:130" name="Na2HPO4" comment="" chebi-id="CHEBI:34683" relevant="false">Na2HPO4</ne>; strand concentration: 20 [mu]M for both CD and Tm experiments; CD was conducted at 260 nm wavelength. dG4T4G4 and related sequences (PG25-28) : 10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.104" epochem-id="EPOCHEM:NEW:COMPOUND:1308" name="sodium phosphate" comment="" chebi-id="WO2007038869:679723" relevant="false">sodium phosphate</ne> <ne type="ONT" id="WO2007038869.HC.class-names.427" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>, 0.1 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.132" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007038869:318736" relevant="false">EDTA</ne>, pH 7 and 200 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.20" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>; strand concentration: 10 [mu]M. &lt;d&gt;dT2G4T2 and related sequences (PGl7-24) : phosphate buffered saline (PBS <ne type="ONT" id="WO2007038869.HC.class-names.428" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>, pH 7.2 at 25[deg.]C) , 137 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.21" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>, 2.7 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.39" epochem-id="EPOCHEM:NEW:FORMULA:131" name="KCl" comment="" chebi-id="CHEBI:32588" relevant="false">KCl</ne>, 1.5 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.46" epochem-id="EPOCHEM:NEW:FORMULA:132" name="KH2PO4" comment="" chebi-id="WO2007038869:547589" relevant="false">KH2PO4</ne>, 8 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.7" epochem-id="EPOCHEM:NEW:FORMULA:130" name="Na2HPO4" comment="" chebi-id="CHEBI:34683" relevant="false">Na2HPO4</ne>; strand concentration: 20 [mu]M; Tm measurements were conducted at 260 nm wavelength. dG4T4G4 and related sequences (PG25-28) : 10 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.105" epochem-id="EPOCHEM:NEW:COMPOUND:1308" name="sodium phosphate" comment="" chebi-id="WO2007038869:679723" relevant="false">sodium phosphate</ne> <ne type="ONT" id="WO2007038869.HC.class-names.429" epochem-id="EPOCHEM:NEW:CLASS:844" name="buffer" comment="" chebi-id="CHEBI:35225" relevant="false">buffer</ne>, 0.1 mM <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.133" epochem-id="EPOCHEM:NEW:COMPOUND:2" name="EDTA" comment="" chebi-id="WO2007038869:318736" relevant="false">EDTA</ne>, pH 7 and 200 mM <ne type="FORMULA" id="WO2007038869.HC.formula-names.22" epochem-id="EPOCHEM:NEW:FORMULA:2" name="NaCl" comment="" chebi-id="CHEBI:26710" relevant="false">NaCl</ne>; strand concentration: 100 [mu]M; Tm measurements were conducted at 295 nm wavelength.
&lt;e&gt;[Delta]Tm (&lt;0&gt;C) is the Tm change of PG17-24 or PG26-27 relative to the control PGl7 or PG25, respectively.
&lt;f&gt;Tm from the reference: Wyatt, J. R., P. W. Davis, et al . (1996) Kinetics of G-quartet-mediated tetramer formation. Biochemistry 25^-. 8002-8008.
&lt;9&gt;n.d. : not determined
&lt;h&gt;Tm from the reference: Lu, M., Q. Guo, et al . (1993) Biochemistry 32_: 598-601.
Claims :
</P>
<P>1. An <ne id="WO2007038869.HC.class-names.487" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> capable of forming a <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.81" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne> comprising at least one <ne id="WO2007038869.HC.class-names.319" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne>.
</P>
<P>2. The <ne id="WO2007038869.HC.class-names.488" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of claim 1, wherein the <ne id="WO2007038869.HC.class-names.320" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne> has a 2' substituent selected from the group consisting of <ne type="LIGAND" id="WO2007038869.HC.ligand-names.66" epochem-id="EPOCHEM:NEW:LIGAND:352" name="fluorine" comment="" chebi-id="CHEBI:24061" relevant="false">fluorine</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.27" epochem-id="EPOCHEM:NEW:LIGAND:1" name="hydroxyl" comment="" chebi-id="CHEBI:29191" relevant="false">hydroxyl</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.58" epochem-id="EPOCHEM:NEW:LIGAND:590" name="amino" comment="" chebi-id="CHEBI:46882" relevant="false">amino</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.32" epochem-id="EPOCHEM:NEW:LIGAND:515" name="azido" comment="" chebi-id="CHEBI:36825" relevant="false">azido</ne>, <ne id="WO2007038869.HC.class-names.535" epochem-id="EPOCHEM:NEW:CLASS:1115" name="alkyl" comment="" chebi-id="CHEBI:22323" relevant="false" type="CLASS">alkyl</ne>, <ne id="WO2007038869.HC.class-names.542" epochem-id="EPOCHEM:NEW:CLASS:1116" name="alkoxy" comment="" chebi-id="CHEBI:22338" relevant="false" type="CLASS">alkoxy</ne>, and <ne id="WO2007038869.HC.class-names.311" epochem-id="EPOCHEM:NEW:CLASS:886" name="alkoxyalkyl groups" comment="" chebi-id="WO2007038869:614727" relevant="false" type="CLASS">alkoxyalkyl groups</ne>.
</P>
<P>3. The <ne id="WO2007038869.HC.class-names.489" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of claim 2, wherein the <ne id="WO2007038869.HC.class-names.308" epochem-id="EPOCHEM:NEW:CLASS:864" name="alkyl group" comment="" chebi-id="CHEBI:22323" relevant="false" type="CLASS">alkyl group</ne> is selected from the group consisting of <ne type="LIGAND" id="WO2007038869.HC.ligand-names.56" epochem-id="EPOCHEM:NEW:LIGAND:457" name="methyl" comment="" chebi-id="CHEBI:29309" relevant="false">methyl</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.54" epochem-id="EPOCHEM:NEW:LIGAND:458" name="ethyl" comment="" chebi-id="CHEBI:37807" relevant="false">ethyl</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.52" epochem-id="EPOCHEM:NEW:LIGAND:520" name="propyl" comment="" chebi-id="CHEBI:26308" relevant="false">propyl</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.50" epochem-id="EPOCHEM:NEW:LIGAND:519" name="butyl" comment="" chebi-id="CHEBI:41264" relevant="false">butyl</ne>, and functionalized <ne id="WO2007038869.HC.class-names.306" epochem-id="EPOCHEM:NEW:CLASS:885" name="alkyl groups" comment="" chebi-id="CHEBI:22323" relevant="false" type="CLASS">alkyl groups</ne> such as <ne type="LIGAND" id="WO2007038869.HC.ligand-names.41" epochem-id="EPOCHEM:NEW:LIGAND:516" name="ethylamino" comment="" chebi-id="WO2007038869:857721" relevant="false">ethylamino</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.44" epochem-id="EPOCHEM:NEW:LIGAND:517" name="propylamino" comment="" chebi-id="WO2007038869:230924" relevant="false">propylamino</ne> and <ne type="LIGAND" id="WO2007038869.HC.ligand-names.47" epochem-id="EPOCHEM:NEW:LIGAND:518" name="butylamino" comment="" chebi-id="WO2007038869:893212" relevant="false">butylamino</ne> groups, the <ne id="WO2007038869.HC.class-names.303" epochem-id="EPOCHEM:NEW:CLASS:884" name="alkoxy group" comment="" chebi-id="WO2007038869:813809" relevant="false" type="CLASS">alkoxy group</ne> is selected from the group consisting of <ne type="LIGAND" id="WO2007038869.HC.ligand-names.9" epochem-id="EPOCHEM:NEW:LIGAND:94" name="methoxy" comment="" chebi-id="WO2007038869:845772" relevant="false">methoxy</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.11" epochem-id="EPOCHEM:NEW:LIGAND:4" name="ethoxy" comment="" chebi-id="CHEBI:42241" relevant="false">ethoxy</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.13" epochem-id="EPOCHEM:NEW:LIGAND:481" name="proproxy" comment="" chebi-id="WO2007038869:290197" relevant="false">proproxy</ne> and functionalized <ne id="WO2007038869.HC.class-names.301" epochem-id="EPOCHEM:NEW:CLASS:883" name="alkoxy groups" comment="" chebi-id="CHEBI:22338" relevant="false" type="CLASS">alkoxy groups</ne> such as <ne type="LIGAND" id="WO2007038869.HC.ligand-names.15" epochem-id="EPOCHEM:NEW:LIGAND:482" name="-O(CH2)q-R" comment="" chebi-id="WO2007038869:713628" relevant="false">-O(CH2)q-R</ne>, where q=2-4 and -R is a -<ne type="LIGAND" id="WO2007038869.HC.ligand-names.69" epochem-id="EPOCHEM:NEW:LIGAND:608" name="NH2" comment="" chebi-id="CHEBI:46882" relevant="false">NH2</ne>, -<ne type="LIGAND" id="WO2007038869.HC.ligand-names.22" epochem-id="EPOCHEM:NEW:LIGAND:421" name="OCH3" comment="" chebi-id="WO2007038869:95589" relevant="false">OCH3</ne>, or - <ne type="LIGAND" id="WO2007038869.HC.ligand-names.2" epochem-id="EPOCHEM:NEW:LIGAND:478" name="OCH2CH3" comment="" chebi-id="WO2007038869:936730" relevant="false">OCH2CH3</ne> group and the <ne id="WO2007038869.HC.class-names.313" epochem-id="EPOCHEM:NEW:CLASS:887" name="alkoxyalkyl group" comment="" chebi-id="WO2007038869:828081" relevant="false" type="CLASS">alkoxyalkyl group</ne> is selected from the group consisting of <ne type="LIGAND" id="WO2007038869.HC.ligand-names.5" epochem-id="EPOCHEM:NEW:LIGAND:479" name="methoxyethyl" comment="" chebi-id="WO2007038869:897528" relevant="false">methoxyethyl</ne> , and <ne type="LIGAND" id="WO2007038869.HC.ligand-names.7" epochem-id="EPOCHEM:NEW:LIGAND:480" name="ethoxyethyl" comment="" chebi-id="WO2007038869:920070" relevant="false">ethoxyethyl</ne> .
</P>
<P>4. The <ne id="WO2007038869.HC.class-names.490" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of claim 3, wherein the functionalized <ne id="WO2007038869.HC.class-names.309" epochem-id="EPOCHEM:NEW:CLASS:864" name="alkyl group" comment="" chebi-id="CHEBI:22323" relevant="false" type="CLASS">alkyl group</ne> is selected from the group consisting of <ne type="LIGAND" id="WO2007038869.HC.ligand-names.42" epochem-id="EPOCHEM:NEW:LIGAND:516" name="ethylamino" comment="" chebi-id="WO2007038869:857721" relevant="false">ethylamino</ne>, <ne type="LIGAND" id="WO2007038869.HC.ligand-names.45" epochem-id="EPOCHEM:NEW:LIGAND:517" name="propylamino" comment="" chebi-id="WO2007038869:230924" relevant="false">propylamino</ne> and <ne type="LIGAND" id="WO2007038869.HC.ligand-names.48" epochem-id="EPOCHEM:NEW:LIGAND:518" name="butylamino" comment="" chebi-id="WO2007038869:893212" relevant="false">butylamino</ne> group and the functionalized <ne id="WO2007038869.HC.class-names.304" epochem-id="EPOCHEM:NEW:CLASS:884" name="alkoxy group" comment="" chebi-id="WO2007038869:813809" relevant="false" type="CLASS">alkoxy group</ne> is selected from the group consisting of <ne type="LIGAND" id="WO2007038869.HC.ligand-names.24" epochem-id="EPOCHEM:NEW:LIGAND:484" name="-0(CH2Jq-R" comment="" chebi-id="WO2007038869:438104" relevant="false">-0(CH2Jq-R</ne>, where q=2-4 and -R is a -<ne type="LIGAND" id="WO2007038869.HC.ligand-names.70" epochem-id="EPOCHEM:NEW:LIGAND:608" name="NH2" comment="" chebi-id="CHEBI:46882" relevant="false">NH2</ne>, -<ne type="LIGAND" id="WO2007038869.HC.ligand-names.23" epochem-id="EPOCHEM:NEW:LIGAND:421" name="OCH3" comment="" chebi-id="WO2007038869:95589" relevant="false">OCH3</ne>, or - <ne type="LIGAND" id="WO2007038869.HC.ligand-names.3" epochem-id="EPOCHEM:NEW:LIGAND:478" name="OCH2CH3" comment="" chebi-id="WO2007038869:936730" relevant="false">OCH2CH3</ne> group
</P>
<P>5. The <ne id="WO2007038869.HC.class-names.491" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of claim 2, wherein the at least one <ne id="WO2007038869.HC.class-names.321" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne> is <ne id="WO2007038869.HC.class-names.330" epochem-id="EPOCHEM:NEW:CLASS:889" name="2'-deoxy-2'- fluoroarabinonucleotide" comment="" chebi-id="WO2007038869:932062" relevant="false" type="CLASS">2'-deoxy-2'- fluoroarabinonucleotide</ne> (<ne id="WO2007038869.HC.class-names.383" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>) .
</P>
<P>6. The <ne id="WO2007038869.HC.class-names.492" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 1-5, wherein the at least one <ne id="WO2007038869.HC.class-names.322" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne> is in a loop of the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.82" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-Tetrad</ne>.
</P>
<P>7. The <ne id="WO2007038869.HC.class-names.493" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claim 1-5, wherein the at least one <ne id="WO2007038869.HC.class-names.323" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne> is a guanosine residue of the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.83" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne>.
</P>
<P>8. The <ne id="WO2007038869.HC.class-names.494" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 1-7, wherein the <ne id="WO2007038869.HC.class-names.495" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> selectively binds thrombin.
</P>
<P>9. The <ne id="WO2007038869.HC.class-names.496" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of claims 8 , wherein the <ne id="WO2007038869.HC.class-names.497" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> has the nucleotide sequence dGGTTGGTGTGGTTGG.
</P>
<P>10. The <ne id="WO2007038869.HC.class-names.498" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of claim 1 having a sequence selected from group consisting of SEQ ID NOS. 1-3 and 4-14.
</P>
<P>11. The <ne id="WO2007038869.HC.class-names.499" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 1-7, wherein the <ne id="WO2007038869.HC.class-names.500" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> selectively binds HIV g[rho]l20.
</P>
<P>12. The <ne id="WO2007038869.HC.class-names.501" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of claim 11, wherein the <ne id="WO2007038869.HC.class-names.502" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> has the nucleotide sequence dTTGGGGTT.
</P>
<P>13. The <ne id="WO2007038869.HC.class-names.503" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of claim 1 having a sequence selected from group consisting of SEQ ID NOS. 19-24.
</P>
<P>14. The <ne id="WO2007038869.HC.class-names.504" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 1-7, wherein the <ne id="WO2007038869.HC.class-names.505" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> is a dG4T4 repeat.
</P>
<P>15. The <ne id="WO2007038869.HC.class-names.506" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of claim 14, wherein the <ne id="WO2007038869.HC.class-names.507" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> is any one of dG4T4G4, dG4T4G4T4G4 and dG4T4G4T4G4T4G4.
</P>
<P>16. The <ne id="WO2007038869.HC.class-names.508" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of claim 1 having a sequence selected from the group consisting of SEQ ID NOS. 26-28.
</P>
<P>17. The <ne id="WO2007038869.HC.class-names.509" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 1-9, 11, 12, 14 and 15 having a sugar phosphate backbone .
</P>
<P>18. The <ne id="WO2007038869.HC.class-names.510" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 1-9, 11, 12, 14, 15 and 17 wherein the <ne id="WO2007038869.HC.class-names.511" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> is a chimera of <ne id="WO2007038869.HC.class-names.528" epochem-id="EPOCHEM:NEW:CLASS:898" name="2'- deoxyribonucleotide" comment="" chebi-id="WO2007038869:739386" relevant="false" type="CLASS">2'- deoxyribonucleotide</ne> (DNA) and <ne id="WO2007038869.HC.class-names.331" epochem-id="EPOCHEM:NEW:CLASS:889" name="2'-deoxy-2'- fluoroarabinonucleotide" comment="" chebi-id="WO2007038869:932062" relevant="false" type="CLASS">2'-deoxy-2'- fluoroarabinonucleotide</ne> (<ne id="WO2007038869.HC.class-names.384" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>) nucleotides.
</P>
<P>19. The <ne id="WO2007038869.HC.class-names.512" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 1-9, 11, 12, 14 and 15, containing at least one internucleotide linkage selected from the group consisting of <ne id="WO2007038869.HC.class-names.181" epochem-id="EPOCHEM:NEW:CLASS:623" name="phosphodiester" comment="" chebi-id="WO2007038869:218685" relevant="false" type="CLASS">phosphodiester</ne>, <ne id="WO2007038869.HC.class-names.197" epochem-id="EPOCHEM:NEW:CLASS:629" name="phosphotriester" comment="" chebi-id="WO2007038869:606591" relevant="false" type="CLASS">phosphotriester</ne>, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.53" epochem-id="EPOCHEM:NEW:COMPOUND:1727" name="phosphorothioate" comment="" chebi-id="WO2007038869:297068" relevant="false">phosphorothioate</ne>, <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.47" epochem-id="EPOCHEM:NEW:COMPOUND:1726" name="methylphosphonate" comment="" chebi-id="CHEBI:45129" relevant="false">methylphosphonate</ne>, <ne id="WO2007038869.HC.class-names.199" epochem-id="EPOCHEM:NEW:CLASS:630" name="boranophosphate" comment="" chebi-id="WO2007038869:315530" relevant="false" type="CLASS">boranophosphate</ne> and any combination thereof.
</P>
<P>20. A method for increasing at least one of nuclease stability or selective binding of an <ne id="WO2007038869.HC.class-names.513" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> comprising replacing at least one nucleotide of the <ne id="WO2007038869.HC.class-names.514" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> with an <ne id="WO2007038869.HC.class-names.324" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne>.
</P>
<P>21. The method of claim 20, wherein the <ne id="WO2007038869.HC.class-names.325" epochem-id="EPOCHEM:NEW:CLASS:888" name="arabinose modified nucleotide" comment="" chebi-id="WO2007038869:127273" relevant="false" type="CLASS">arabinose modified nucleotide</ne> is <ne id="WO2007038869.HC.class-names.332" epochem-id="EPOCHEM:NEW:CLASS:889" name="2'-deoxy-2'- fluoroarabinonucleotide" comment="" chebi-id="WO2007038869:932062" relevant="false" type="CLASS">2' -deoxy-2' -fluoroarabinonucleotide</ne> (<ne id="WO2007038869.HC.class-names.385" epochem-id="EPOCHEM:NEW:CLASS:890" name="FANA" comment="" chebi-id="WO2007038869:923845" relevant="false" type="CLASS">FANA</ne>).
</P>
<P>22. The method of any one of claims 20-21, wherein the <ne id="WO2007038869.HC.class-names.515" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> forms a <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.84" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne>.
</P>
<P>23. The method of claim 22, wherein the at least one nucleotide being replaced is in a loop of the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.85" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne>.
</P>
<P>24. The method of claim 22, wherein the at least one nucleotide being replaced is a guanosine residue of the <ne type="CHEMICAL" id="WO2007038869.HC.chemical-names.86" epochem-id="EPOCHEM:NEW:COMPOUND:1730" name="G-tetrad" comment="" chebi-id="WO2007038869:789734" relevant="false">G-tetrad</ne>.
</P>
<P>25. The method of any one of claims 20-24 wherein the <ne id="WO2007038869.HC.class-names.516" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> selectively binds thrombin and has the nucleotide sequence dGGTTGGTGTGGTTGG.
</P>
<P>26. The method of any one of claims 20-24 wherein the <ne id="WO2007038869.HC.class-names.517" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> selectively bind HIV gpl20 and has the nucleotide sequence dTTGGGGTT.
</P>
<P>27. The method of any one of claims 20-24 wherein the <ne id="WO2007038869.HC.class-names.518" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> is a dG4T4 repeat and is any one of dG4T4G4, dG4T4G4T4G4 and dG4T4G4T4G4T4G4.
</P>
<P>28. A pharmaceutical composition comprising the <ne id="WO2007038869.HC.class-names.519" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 1-19 along with a pharmaceutically acceptable carrier.
</P>
<P>29. A pharmaceutical composition comprising the <ne id="WO2007038869.HC.class-names.520" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 8-10 along with a pharmaceutically acceptable carrier.
</P>
<P>30. A pharmaceutical composition comprising the <ne id="WO2007038869.HC.class-names.521" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 11-13 along with a pharmaceutically acceptable carrier.
</P>
<P>31. A pharmaceutical composition comprising the <ne id="WO2007038869.HC.class-names.522" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 14-16 along with a pharmaceutically acceptable carrier.
</P>
<P>32. Use of the <ne id="WO2007038869.HC.class-names.523" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 8-10 for the preparation of a medicament for inhibiting thrombin.
</P>
<P>33. A method of inhibiting thrombin in a patient in need thereof, comprising administering a therapeutically effective amount of the composition of claim 29.
</P>
<P>34. A commercial package comprising the composition of claim
</P>
<P>29 together with instructions for its use for inhibiting thrombin and increasing blood clotting times.
</P>
<P>35. Use of the <ne id="WO2007038869.HC.class-names.524" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 11-13 for the preparation of a medicament for treating or preventing HIV infection.
</P>
<P>36. A method of treating or preventing HIV infection in a patient in need thereof, comprising administering a therapeutically effective amount of the composition of claim 30.
</P>
<P>37. A commercial package comprising the composition of claim
</P>
<P>30 together with instructions for its use for treating or preventing HIV infection.
</P>
<P>38. Use of the <ne id="WO2007038869.HC.class-names.525" epochem-id="EPOCHEM:NEW:CLASS:897" name="aptamer" comment="" chebi-id="WO2007038869:676574" relevant="false" type="CLASS">aptamer</ne> of any one of claims 14-16 for the preparation of a medicament for treating cancer.
</P>
<P>39. A method of treating or preventing cancer in a patient in need thereof, comprising administering a therapeutically effective amount of the composition of claim 31.
</P>
<P>0. A commercial package comprising the composition of claim 31 together with instructions for its use for treating or preventing cancer.
</P></DIV>
<DIV><P>
</P></DIV>
</BODY>
</PAPER>
